**Review**

**Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications**

Dimitrios Tsiapalis and Lorraine O’Driscoll *

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland; tsiapald@tcd.ie

* Correspondence: lodrisc@tcd.ie; Tel.: +353-1-8962822

Received: 24 March 2020; Accepted: 14 April 2020; Published: 16 April 2020

**Abstract:** Mesenchymal stem cells (MSCs) are being extensively investigated for their potential in tissue engineering and regenerative medicine. However, recent evidence suggests that the beneficial effects of MSCs may be manifest by their released extracellular vesicles (EVs); typically not requiring the administration of MSCs. This evidence, predominantly from pre-clinical in vitro and in vivo studies, suggests that MSC-EVs may exhibit substantial therapeutic properties in many pathophysiological conditions, potentially restoring an extensive range of damaged or diseased tissues and organs. These benefits of MSC EVs are apparently found, regardless of the anatomical or body fluid origin of the MSCs (and include e.g., bone marrow, adipose tissue, umbilical cord, urine, etc). Furthermore, early indications suggest that the favourable effects of MSC-EVs could be further enhanced by modifying the way in which the donor MSCs are cultured (for example, in hypoxic compared to normoxic conditions, in 3D compared to 2D culture formats) and/or if the EVs are subsequently bio-engineered (for example, loaded with specific cargo). So far, few human clinical trials of MSC-EVs have been conducted and questions remain unanswered on whether the heterogeneous population of EVs is beneficial or some specific sub-populations, how best we can culture and scale-up MSC-EV production and isolation for clinical utility, and in what format they should be administered. However, as reviewed here, there is now substantial evidence supporting the use of MSC-EVs in tissue engineering and regenerative medicine and further research to establish how best to exploit this approach for societal and economic benefit is warranted.

**Keywords:** mesenchymal stem cells; extracellular vesicles; tissue damage; tissue engineering and regeneration; regenerative medicine

---

**1. Introduction**

For some patients with end-organ dysfunction, whole organ transplantation is an established treatment option [1]. However, the limited availability of suitable autologous tissues, the risk of immune-mediated rejection, the required chronic immunosuppression treatment, and the possibility of disease transmission, highlight the need of new therapeutic approaches [2]. Tissue engineering and regenerative medicine strategies have triggered intense attention due to the potential to develop remedies for damaged, malfunctioning, or injured tissues [3]. Cell-based therapies, in their natural form or modified/engineered for a specific purpose, hold much promise in this regard. Indeed, in light of their multiple sources as well as therapeutic versatility, mesenchymal stem cells (MSCs) have been proposed as the most appropriate cell source for these applications [4,5]. As stem cells, they exhibit beneficial characteristics as compared to terminally differentiated cells, including the potential to circumvent immuno-reaction in vitro and in vivo and to differentiate towards a broad range of specific
cell lineages [6,7]. MSCs can be isolated from various tissue types including bone marrow, adipose, umbilical cord, peripheral blood, liver, periodontal ligament, lung and many others [8]. However, despite their potential and promise, MSCs face many challenges, such as their variability, scalability and delivery, as well as ethical considerations and safety issues [9–13], which challenge their clinical utility.

EVs are heterogeneous lipid bilayer-surrounded vesicles secreted by all cell types, not only MSCs, and act as mediators of intercellular communication. EVs are involved in numerous physiological and pathophysiological biological processes, including modulating immune responses, homeostasis maintenance, coagulation, inflammation, angiogenesis, and cancer progression [14–17]. According to their size, dimension and origin, they can be classified in many ways, with the preferred terms now being small EVs, medium-sized EVs, and large EVs [18,19].

There is increasing evidence that many, if not all, of the beneficial effects of MSCs may be attributed to their paracrine action via the release of extracellular vehicles (EVs), rather than cellular engraftment and response to the site of injury [20–22]; suggesting that MSC-EVs can produce any therapeutic benefits of MSCs [23]. Added to their attractiveness, compared to the original MSCs, MSC-EVs cannot self-replicating, preventing safety concerns associated with cell therapy, such as uncontrolled cell division and cellular contamination with tumorigenic cells [24]. Moreover, as MSCs often require invasive procedures in order to be isolated, approaches that only require them to be cultured in vitro and their released product used (i.e., EVs) gives hope for increased scalability and yield per MSC batch [25], with filtration suggested to be suitable sterilisation because of their small size [26].

Herein, we review current advancements of the therapeutic potential of MSC-EVs in tissue engineering and regenerative medicine (Figure 1), considering the molecular mechanisms suggested for the MSC-EV action where possible.
2. EV Biogenesis and Characterisation

Small-size EVs, most of which were previously termed as exosomes, are vesicles ranging from 30–150 nm. The biogenesis of the small-size EVs occurs initially with the formation of early endosomes from endocytoses of the cell membrane (Figure 2). During the process of maturation, the early endosomes become endosomes or multivesicular bodies and they begin to accumulate intraluminal vesicles, which either degraded by lysosomes or are released as exosomes in the extracellular space [27]. Medium- and large-size EVs, previously described as microvesicles or ectosomes, are large vesicles between 100–1000 nm diameter. Their biogenesis occurs via the direct budding of the cell membrane and releasing into the extracellular space [28,29]. While apoptotic bodies are also large-size vesicles, ranging from 1–5 mm, they originate specifically from apoptotic cells [30].

![Figure 2. EV biogenesis and secretion: exosomes are assembled in multivesicular bodies where specific cargos are sorted into exosomes and subsequently released in the extracellular space. Microvesicles are formed from budding of the cell membrane. Apoptotic bodies are generated from apoptotic cells.](image)

As extensively review by the EV research community, according to their cellular origin and the mechanism of secretion, EVs carry somewhat distinct surface markers [21]. Tetraspanin proteins such as CD9, CD81, and CD63 are enriched in the membrane of exosomes and so they are often used to help quality small EVs as exosomes. Furthermore, small EVs may be distinguished by the presence of proteins involved in their biogenesis, including annexin, flotillin, auxiliary proteins (ALIX, TSG101, VPS4), components of the endosomal sorting complex required for transport (ESCRT), GTPase and heat shock proteins (HSP70 and HSP90) [19]. In contrast, CD40 ligand and annexin A1 are associated with medium- and large-size EVs [31,32], whereas apoptotic bodies carry annexin V [33]. Additionally, EV sub-populations contain a range of forms of lipids: cholesterols, diglycerides, sphingolipids (including sphingomyelin and ceramide), phospholipids, and glycerophospholipids, which are key components for the structure, function and biogenesis of EVs [34]. It has been well established that EVs also carry nucleic acids that can be transferred to secondary cells, affecting their cellular processes [17]. Among these, for example, the mRNA content of some EVs has been suggested to significantly influence the biological function of neighbouring cells, such as cell differentiation, transcription, cell proliferation...
and immune regulation. Similarly, many studies have reported miRNA within EVs being transferred to recipient cells and subsequently altering the gene expression and phenotype of those cells e.g., modulating cycle, apoptosis, migration, inflammation, and neo-angiogenesis [35–38].

While these studies related to EV biogenesis and characterisation are not all focussed on MSCs, it seems that MSC-EVs are also heterogeneous, carry cargo such as proteins, nucleic acids and lipids, and are involved in cell-to-cell communication.

3. EV Isolation Methods

A challenge for MSC-EV in regenerative medicine, particularly when considering towards clinical utility, is the lack of standardisation in EV isolation methods. Of course, this is not unique to MSC-EVs; there are many options but no standardised method for the isolation and purification of EVs. A world-wide survey by the International Society for Extracellular Vesicles (ISEV) [39], considering EV isolation from any and all sources showed ultracentrifugation-based methods to be most commonly used, although a range of other approaches have been taken to overcome challenges regarding ultracentrifugation including the need for an ultracentrifuge, low-throughput of samples, and potential damage to EVs caused by high-speed centrifugation [40,41]. To this end, alternative methods such as filtration/ultrafiltration, size exclusion chromatography, immunoprecipitation, and precipitation with reagents such as PEG have been utilised, with varying degrees of efficacy in terms of purity and quantity [42]. Thus, combinations of two or more isolation methods are gaining popularity in order to increase EV purity [43]. Moreover, EVs can be modified to enhance their therapeutic potential. Thus, EVs can be incorporated with elements including drugs, antibodies, proteins and RNA for targeted delivery and with molecules such as lipophilic dyes and amino-reactive fluorophores for in vitro and in vivo traceability. In that cases, novel EV-like approaches have been generated such as bio-engineered EVs, EV-mimetic nanovesicles and EV-based semi-synthetic vesicles, as described and reviewed by others [44–48]. Specifically in relation to MSC-EVs, a range of methods of EV isolation from different sources and for different applications to address clinical problems (in the nervous system, heart, bone, cartilage, kidney, liver, muscle, wounds, and other tissues/organ) have been reported, as summarised in Table 1.

4. MSC-EVs in Tissue Engineering and Regeneration

4.1. Nervous Regeneration

The nervous system is a crucial component of the body and any injury or a disease to it can cause serious or potentially lethal consequences. Nerve repair has long remained a significant objective in regenerative medicine, due to the physiological system complexity and the limited healing capacity [49]. A plethora of strategies have been employed to correct peripheral nerve injuries. In one such study, EVs derived from rat bone marrow mesenchymal stem cells (BMMSCs), were reported to stimulate nerve regeneration after sciatic peripheral nerve crush injury in a rat model. The benefit from the EV was manifest as improved sciatic function index after injury, enhanced histomorphometric repair in nerve regeneration, and increased expression of growth associated protein 43 (GAP43), a marker of axon regeneration [50]. Similarly, peripheral nerve recovery was noticed when EV from human umbilical cord mesenchymal stem cells (UCMSCs) were applied in the site of sciatic nerve defect in rats. EVs aggregated at the site of the nerve injury, prompted the generation of axons and Schwann cells that surrounded individual axons, reduced denervated muscle atrophy and modulated inflammation via down-regulation of pro-inflammatory cytokines (interleukin [IL]-6 and IL-1β) and up-regulation anti-inflammatory cytokines (IL-10) [51]. Another study suggested that EVs from rat adipose-derived mesenchymal stem cells (ADMSCs) promoted peripheral nerve regeneration and neurite growth in sciatic nerve defects, assumed to be through Schwann cell (SC) modulation [52]. Mechanistically, Schwann cells stimulation and proliferation in the damaged neurons relies on the perinuclear location of ADSC-EVs and their accumulation in vesicular-like structures within the Schwann, which indicates...
an endocytosis-mediated internalization pathway [53]. A more detailed mechanism of peripheral nerve regeneration upon treatment with gingiva MSC-EVs illustrated that the proliferation and migration of Schwann cells occur mainly via the activation of c-Jun N-terminal Kinase (JNK) pathway and the up-regulation of c-Jun, Notch1, glial fibrillary acidic protein (GFAP), and SRY (sex determining region Y)-box 2 (Sox2) characteristic genes of de-differentiation or repair phenotype of Schwann cells [54].

Research efforts showed also the therapeutic efficacy of MSC-EVs in the context of central nervous system (CNS) repair. In a model of middle cerebral artery stroke (MCA), EVs derived from rat BM-MSCs led to neurite outgrowth by transfer of miR-133b to neural cells [55]. Systemic administration of rat BM-MSC-EVs increased the axonal density and synaptophysin-positive areas along the ischemic boundary zone of the cortex and striatum in MCA rats. This was accompanied by enhanced expression of newly synthesised doublecortin (a marker of neuroblasts [56]) and von Willebrand factor (a marker of endothelial cells [57]) as compared to the untreated controls, suggesting thus neurite remodelling, neurogenesis and angiogenesis as a novel treatment for stroke [58].

With respect to brain damage, rat BM-MSC-EVs have been assessed in traumatic brain injury (TBI) rat models. Overall, EV treatment improved recovery of brain function after TBI by increasing the number of newly-generated immature and mature neurons in the dentate gyrus as well as the number of newly-generated endothelial cells in the lesion boundary zone and dentate gyrus [59].

The impact of MSC-EVs has also been investigated in spinal cord injuries (SCI). SCI is frequently associated with microvascular stability disruption and an increase in blood-spinal cord barrier (BSCB) permeability, mainly caused by abnormal migration of pericytes [60,61]. Notably, treatment with mouse BM-MSC-EVs inhibited the migration of pericytes and thereby improved the structural integrity of the BSCB and, in turn, the motor function in a SCI rat model [62]. Another potent mechanism of spinal cord recovery upon BM-MSC-EVs treatment suggested the prevention of neuronal apoptosis through the activation of the Wnt/β-catenin signalling pathway [63]. Furthermore, in an SCI model, modification of rat BM-MSC-EVs with miR-133b caused activation of the ERK1/2, STAT3 pathway. This resulted in enhanced neuron preservation, axon regeneration, and locomotor function, when compared to treatment with BM-MSC-EVs that had not been modified to carry miR-133b [64].

MSC-EVs from human placenta have been tested in a multiple sclerosis mouse (MS) model. Here, MSC-EVs induced myelin regeneration in vitro by endogenous oligodendrocyte precursor cells differentiation into mature myelinating oligodendrocytes and increased myelination in the spinal cord of treated mice, following by improved motor function outcomes [65]. Furthermore, EVs from human BM-MSCs that had been stimulated with interferon-gamma (IFN-γ), reduced neuroinflammation and demyelination improving the motor skills in a MS mouse autoimmune encephalomyelitis (EAE) model [66].

Additionally, in a mouse model of Alzheimer’s disease, MSC-EVs (the source of the MSCs was not detailed) promoted neurogenesis and cognitive function recovery [67].

4.2. Cardiac Regeneration

Endogenous myocardial repair after damage is very slow and is dependent on the limited self-division of pre-existing cardiomyocytes and the recruitment and differentiation of resident cardiac stem cells [68–70]. The exogenous cell-free approach of using MSC-EVs therapeutically has emerged to address the insufficient responses to myocardial damage typically achievable by endogenous mechanisms. Initial studies established that human embryonic-derived MSC-EVs could reduce infarct size in a mouse model of myocardial ischemia/reperfusion injury (MI) [71], through the activation of the PI3K/Akt signalling pathway, which increased myocardial viability and inhibited adverse remodelling [72]. Taken into consideration this observation, human UCMSCs were subsequently transfected with Akt, which was found to be at high levels in their released EVs. Compared to the non-modified human UCMSC-EVs, this Akt-carrying human UCMSC-EVs complex further accelerated endothelial cell proliferation, migration and tube-like structure formation in vitro and blood vessel formation in vivo [73].
In this setting, some studies have done direct comparisons of MSCs versus MSC-EVs and as a result have highlighted the added beneficial effects of EVs compared to their MSCs of origin. In one such study, murine induced pluripotent mesenchymal stem cells (iPSCs)-EVs and human amniotic fluid-derived mesenchymal stem cells (hAFS) were found to improve cardiac repair in MI murine models and trigger cardiac regeneration via paracrine modulation of endogenous mechanisms. The administered EVs also exhibiting a safer profile when compared to the administration of their cells of origin [74,75]. However, in another MI rat model study, combinatorial treatment with both rat BMMSCs and their derived EVs further improved cardiac function, reduced infarct size, and increased neovascularisation when compared to experimental groups treated with either BMMSCs or BMMSC-EVs alone [76].

Hypoxia pre-conditioning of human BMMSCs has been reported to enhance cells’ biological activities in vitro [77], whilst showed to improve the effectiveness of Cynomolgous monkey BMMSCs when implanted as a treatment of MI in monkeys [78]. Interestingly, hypoxia positively influenced the therapeutic efficacy of the secreted EVs. Hypoxia-elicted human BMMSC-EVs (1% O₂ for 72 h) showed higher cardiac regeneration in a rat MI model than BMMSCs-EVs isolated under normoxia conditions; the mechanism reported as responsible was by increasing angiogenesis in the site of infract region [79]. Moreover, hypoxia-reconditioning murine and rat BMMSC-EVs (at either 1% O₂ for 72 h or 0.5% O₂ for 24 h) prevented cardiomyocyte apoptosis through the enrichment of miR-125b-5p-EVs and miR-210-EVs. The associated mechanism here was suppression of pro-apoptotic genes p53 and BCL2-antagonist/killer 1 (BAK1) and increased recruitment of cardiac progenitor cells in the infarcted heart [80,81].

As an alternative approach to injecting MSC-EVs to the cardiac defect, they can be encapsulated to hydrogels for controlled and targeted administration. Hence, sustain release profile and increased cardiac regeneration was noticed when human UCMSC-EVs were loaded in functional peptide hydrogels. Specifically, the EV/hydrogel complex improved the myocardial function by reducing inflammation, fibrosis and apoptosis, and by promoting angiogenesis in infarcted border zone of rat hearts [82].

4.3. Bone Regeneration

The paracrine effects of MSCs —through the use of their EVs— also offer a potential alternative approach for skeletal regeneration. To this end, EVs from different sources of MSCs are being investigated for bone reconstruction after injury. It was noted that human BMMSC-EVs and human iPSCs-EVs stimulated osteogenic differentiation of BMMSCs in vitro, and bone formation and angiogenesis BMMSCs in vivo in rat models with critical-sized calvarial defects [83,84]. To enhance the bone healing, the human BMMSC-EVs were modified with dimethyloxaloylglycin, which resulted in further stimulation of angiogenesis through the Akt/mTOR pathway [85]. The efficacy of EVs derived from human ADMSCs towards bone regeneration was also enhanced by pre-conditioning the MSCs with the cytokine tumour necrosis factor-alpha (TNF-α), as was evidenced by increased proliferation and osteogenic differentiation of osteoblastic cells in vitro [86]. Furthermore, in a femoral shaft fracture model of CD9⁷⁻/⁻ mice whose bone healing capacity is impaired compared to that of wild-type equivalents, administration of human BMMSC-EVs rescued the delay in fracture healing, and accelerated bone repair in wild types [87].

For dental regeneration, the addition of EVs derived from human dental pulp MSCs resulted in odontogenic differentiation in vitro as a results of endocytosis of the EVs, subsequent activation of the P38 mitogen activated protein kinase (MAPK) pathway, and regeneration of dental pulp-like tissue in a tooth root slice model [88]. Moreover, MSC-EVs promoted periodontal ligament cell migration and proliferation through CD73-mediated adenosine receptor activation of pro-survival Akt and ERK signalling and periodontal regeneration in a rat periodontal defect model [89].

With the aim of augmenting scaffold performance and thereby improving bone healing, tissue engineered-constructs have been combined with MSC-EVs. Thus, human ADMSC-EVs were immobilised to poly (lactic-co-glycolic acid) and biotin-doped polypyrrole titanium scaffolds. In vitro
studies of scaffolds functionalised with the EVs versus unmodified scaffolds showed the former to result in higher osteo-inductivity of BMMSCs and osteoblasts, while in vivo studies using murine models of bone defects showed significantly greater bone tissue and mature collagen formation [90,91]. Additionally, human BMMSC-EVs loaded into tricalcium phosphate scaffolds enhanced bone healing of calvarial defects by activation PI3K/Akt signalling pathway [92], whilst rat BMMSC-EVs encapsulated into decalcified bone matrix scaffolds stimulated bone regeneration by promoting vascularisation in the grafts [93]. Moreover, three-dimensional polylactic acid scaffolds functionalised with human gingival MSCs have been used as a therapeutic tool for bone tissue engineering, with promising osteogenic properties and response in rat models of cortical calvaria bone damage [94].

4.4. Cartilage Regeneration

Articular cartilage has limited intrinsic regenerative capacity upon injury and if poorly healed may lead to osteoarthritis (OA); a severe disease accompanied with loss of joint function and devastating pain [95]. MSC-EVs from various cell sources provide new insights for the development of cell-free therapies for the treatment of cartilage injuries and OA. The therapeutic efficacy of MSC-EVs over their cells of origin for the treatment of OA was highlighted in a comparison study using amniotic fluid MSCs and their derived EVs. EV-treated defects showed superior pain tolerance level and improved histological scores than the MSC-treated defects [96]. Furthermore, human BMMSC-EVs have been reported to promote in vitro cartilage regeneration by triggering the production of collagen type II and proteoglycans of chondrocytes isolated from OA patients [97], both of which are extracellular matrix (ECM) components essential for the proper cartilage repair [98]. It is widely accepted that OA is associated with cartilage degradation mediated mainly by Wnt5A, a non-canonical Wnt protein, which can activate matrix metalloproteinases (MMPs) and reduce the formation of cartilage ECM [99]. Human BMMSC-EVs modified to be enriched with miR-92a-3p have been reported to suppress cartilage degradation and promote cartilage repair in vitro and in an in vivo OA mouse model, as a result of miR-92a-3p targeting Wnt5A [100]. Furthermore, pre-conditioning of rat MSCs with transforming growth factor beta (TGFβ) enhanced the quantities of miR-135b in the resulting EVs, which stimulated chondrocyte proliferation in vitro through specificity protein 1 (Sp1) regulation and cartilage tissue repair in a rat model of OA [101].

In studies applying human embryonic MSC-EVs in rat and mouse models with osteochondral defects, it was noted that osteochondral regeneration was mediated through distinct well-orchestrated mechanisms, such as by enhancing chondrocyte proliferation; attenuating apoptosis; and regulating immune reactivity in the site of the injury; by balancing the synthesis and degradation of cartilage ECM and by restoring matrix homeostasis [102–105].

In addition to enriching EVs with specific miRNA as summarised above, other strategies have been used to augment the potency of MSC-EVs in cartilage repair. For instance, three-dimensional culture of UCMSCs in a hollow-fibre bioreactor resulted in a higher yield of EVs and superior therapeutic efficacy in a rabbit cartilage defect model, compared to MSC-EVs from conventional 2D cultures [106]. To ensure that MSC-EVs are retained at the site cartilage injury, human iPSC-EVs have been incorporated with in situ hydrogel glue. This acellular tissue patch was found to integrate with native cartilage matrix and promote cell deposition at cartilage defect sites, resulting in functional cartilage repair [107]. 3D printing has been described as the next generation of fabrication techniques in tissue engineering that enable the development of complex forms with high precision [108]. Interestingly, BMMSC-EVs together with cartilage ECM/gelatin methacrylate hydrogel have been used as bio-inks for the design of a bio-scaffold. The resulting 3D printed device promoted the targeted delivery of EVs, preventing mitochondrial dysfunction in degenerative chondrocytes in vitro, and facilitated the cartilage regeneration in an in vivo osteochondral defect rabbit model [109].
4.5. Kidney Regeneration

The number of studies using MSC-EVs for the treatment of acute kidney injuries (AKI) and chronic kidney damage (CKD) is continuously increasing, suggesting this strategy may be a promising approach for kidney regeneration. Initially it was established that human BMMSC-EVs accelerated the recovery of injured tubular cells, stimulated cell proliferation, prevented apoptosis and supported functional recovery of glycerol-induced AKI [110]. The suggested route of MSC-EV action involved the delivery of genetic material—such as mRNAs and miRNAs—to injured renal cells, contributing to anti-inflammatory, anti-apoptotic, anti-fibrotic, and pro-angiogenesis effects on AKI [111,112]. Another reported mechanism of renal repair in response to BMMSC-EVs treatment includes the horizontal transfer of human IGF-1 receptor mRNA, which is present in MSC-EVs, to tubular cells [113]. Moreover, administration of human and mice BMMSC-EVs in rat and mice AKI models, respectively, protected the animals from AKI and improved renal function; by inhibiting apoptosis and stimulating tubular epithelial cell proliferation [114,115]. In a cisplatin-induced toxic AKI mouse model, human BMMSC-EVs ameliorated renal function and morphology, and improved survival. Considering the mechanism responsible for this in vitro in cisplatin-treated human tubular epithelial cells, it was shown that the EVs up-regulated anti-apoptotic genes (B-cell lymphoma extra-large B-cell lymphoma 2 and baculoviral IAP repeat containing 8) and down-regulated genes that contribute in the execution-phase of cell apoptosis (caspase-1, caspase-8 and lymphotoxin alpha) [116]. A significant better EV efficacy followed by improved renal function was noticed when mice BM-MSC-EVs were loaded to self-assembling peptide nanofiber hydrogels, for control and targeted release of EVs on the site of mice AKI models after ischaemia-reperfusion [117]. Aside from bone marrow, MSC-EVs from other tissues have been isolated and evaluated for renal regeneration. In one such study, human UCMSC-EVs induced in vitro and in vivo renal repair in rat AKI models (cisplatin-induced and unilateral), through reducing oxidative stress and cell apoptosis, promoting cell proliferation, and tubular cells de-differentiation [118,119]. Similar renal regeneration was observed when EVs derived from human Wharton’s Jelly MSCs were applied in AKI rat models. It was also reported that EVs improved renal function by enhancing tubular cell proliferation and reducing inflammation and apoptosis via mitochondrial fission [120,121]. EVs isolated from human glomerular MSCs and liver MSCs have also been credited with stimulating recovery after AKI [122,123].

Several studies have assessed the influence of MSC-EVs in models of chronic kidney damage (CKD) mainly caused by diabetes [124]. Human urinary MSC-EVs have been reported to prevent CKD progression, by inhibiting podocyte apoptosis and promoting vascular regeneration and cell survival in a rat model of streptozotocin-induced diabetic nephropathy [125]. Another study revealed an improvement of renal morphology with profound anti-apoptotic behaviour of tubular epithelial cells when urinary MSC-EVs were injected into diabetic mice [126]. Human BM-MSC-EVs and human liver MSC-EVs inhibited fibrosis and prevented its progression in a mouse model of diabetic nephropathy mediated by miRNAs capable of down-regulating profibrotic genes [127]. Analogous observations were noticed upon administration of human liver MSC-EVs in a CKD model induced by aristolochic acid [128]. Murine BM-MSC-EVs protected against renal injury both in vitro and in vivo by microRNA-dependent repair in CKD mice models of surgical 5/6 nephrectomy of the kidney tissue [129,130]. Furthermore, injection of human BM-MSC-EVs repaired the damage to apical and basolateral membranes and mitochondria of kidney proximal tubules, and improved renal function in a cadmium medaka model resembling CKD due to long-term environmental exposure to heavy metal [131]. In a clinical trial in forty CKD patients stage III and IV (n = 20 administered MSC-EVs, n = 20 administered placebo) it was observed that MSC-EVs derived from umbilical cord are safe and were able to ameliorate the progression of CDK in grade III-IV CKD patients [132].

4.6. Liver Regeneration

Evaluating the potential benefits of MSC-EVs in relation to liver disease, in a carbon tetrachloride (CCl4)-induced liver injury mouse model human embryonic MSC-EVs were found to promote hepatic
regeneration, by increasing hepatocyte proliferation and reduced hepatocyte apoptosis [133]. Moreover, human iPSC-EVs enhanced hepatic regeneration in hepatic ischemia-reperfusion injury rat models, by inhibiting apoptosis of hepatic cells, suppressing inflammatory responses, and attenuating the oxidative stress response [134]. Human iPSC-EVs were also reported to induce hepatocyte proliferation in vitro and in vivo in a dose-dependent manner, which is related to the activation of sphingosine kinase and sphingosine-1-phosphate signalling pathway [135], known to promote cell proliferation in various cell types [136–138]. Similarly, treatment with human UCMSC-EVs has been shown to ameliorate the infiltration of neutrophils and diminish oxidative stress in hepatic tissue; therefore protecting against hepatic apoptosis [139]. To further enhance the benefits of EVs, human embryonic MSC-EVs were encapsulated in PEG hydrogels for sustain systemic delivery against hepatic failure. Here, EVs accumulated in the liver of the rat model of chronic hepatic fibrosis for prolonged time, exerting superior anti-apoptosis, anti-fibrosis and regenerative properties as compared to conventional EV injection [140].

4.7. Muscle Regeneration

The influence of MSC-EVs have been also assessed in skeletal muscle regeneration. For example, human BMMSC-EVs were found to augment myogenesis and angiogenesis in vitro (mediated by miRNAs such as miR-494) and to enhanced muscle regeneration [141]. Moreover, it was noted that EVs derived from amniotic fluid MSCs contain a spectrum of proteins and miRNAs capable of regulating inflammation and angiogenesis which, in turn, underpin skeletal muscle regeneration [142]. Bioinformatic (miRNA profile and proteomics) analysis of a study assessing the regenerative effect of human ADMSC-EVs on muscle injury showed that repair was mediated by factors distributed both within MSC-EVs and the soluble fraction of the secretome [143].

As a preventative measure, EVs isolated from human ADMSCs have been tested as a means to prevent muscle injuries related to torn rotator cuffs. Here, MSC-EV treatment prevented the atrophy, fatty infiltration, inflammation, and vascularisation of muscles in a rat model of torn rotator cuffs and, also, increased the myofiber regeneration and biomechanical properties of the muscles in rotator cuffs [144]. Furthermore, human urine-derived MSC-EVs promoted repair of pubococcygeus muscle injury in rat models of stress urinary incontinence, through stimulating phosphorylation of extracellular-regulated protein kinases and the activation, proliferation, and differentiation of muscle satellite cells [145]. Additionally, human ASC-EVs have recently been shown to prevent muscle damage in a mouse model of critical hindlimb ischemia, mainly through neuregulin 1 protein (NRG1)-mediated signals playing a crucial role in angiogenesis, prevention of inflammation, and muscle protection [146].

4.8. Wound Healing

Wound healing is a dynamic process that requires a complex of molecular and cellular events, including cellular migration, proliferation, angiogenesis, ECM deposition, and tissue remodelling [147]. Wounds that exhibit impaired or improper healing have failed to progress through the normal stages of healing i.e., homeostasis, inflammation, proliferation, and remodelling; leading to the formation of excessive scars [148]. Several studies have demonstrated the beneficial activities of MSC-EVs for various chronic wounds. In one such study, BMMSC-EVs enhanced, in a dose-dependent manner, the ex vivo proliferation and migration of fibroblasts from healthy donors and chronic wound patients. These EVs also mediated tube formation by endothelial cells, through the activation of pathways (Akt, ERK, and STAT3) involved in wound healing [149]. Another in vitro study suggested that cutaneous wound healing could be facilitated by increasing collagen synthesis and angiogenesis following treatment with human iPSC-EVs [150]. Higher collagen and elastin synthesis was also noted when human ADMSC-EVs were added to photo-damaged human dermal fibroblasts in vitro [151]. In vivo using a mouse skin incision model, injection of human ADMSC-EVs accelerated wound healing via modifying the phenotypic characteristics of fibroblasts. Specifically, collagen I and III distributions secreted by fibroblasts were increased in the early stage of wound healing while, in the late stage, collagen
synthesis was diminished to reduce scar formation [152]. EVs from the same source were reported to trigger the migration and proliferation of keratinocytes and fibroblasts in vitro and in vivo in excisional wound-splitting rat models, by a mechanism involving the activation of Akt pathway [153]. IncRNA metastasis-associated lung adenocarcinoma transcript 1 found in human ADMSC-EVs contributed significantly to the migration and proliferation of dermal fibroblasts, promoting wound closure in a rat model of ischemic wound healing [154]. In a comparison study examining the effect of rabbit ADMSC-EVs and BMMSC-EVs on rat cutaneous wound models, treatment with ADMSC-EVs showed significant better healing [155].

Table 1. MSC-EVs in tissue engineering and regenerative medicine applications.

| Injury/Damage                  | Cell Source | Isolation Method | Administration Route/Quantity       | Main Findings from Studies Evaluating These EVs                                      |
|-------------------------------|-------------|------------------|-------------------------------------|---------------------------------------------------------------------------------------|
| Sciatic peripheral nerve crush| Rat BMMSCs  | Ultracentrifugation (100,000×g) | Injection/45 μg total EV protein in 30 μL PBS | Improved sciatic function index, enhanced histomorphometric repair in nerve regeneration and increased GAP-43 expression [50] |
| Sciatic peripheral nerve crush| Human UCMSs | Differential centrifugation and ultracentrifugation (100,000×g) | Injection/100 μg total EV protein | Generation of axons and Schwann cells, reduction of denervated muscle atrophy and modulation of inflammation [51] |
| Sciatic peripheral nerve crush| Rat ADMSCs  | Differential centrifugation and ultracentrifugation (100,000×g) | Injection/details not provided | Peripheral nerve regeneration and neurite growth in sciatic nerve defects through Schwann cell (SC) modulation [52] |
| Peripheral nerve injury (in vitro) | Rat ADMSCs  | Total Exosome isolation reagent kit (Invitrogen) | 2 and 8 μg total EV protein | Enhanced proliferation of Schwann cells in the site of peripheral nerve injuries via internalisation [53] |
| Sciatic peripheral nerve crush| Human gingiva MSCs | ExoQuick-TC kit (System Biosciences) | EV-scaffold transplantation/40 μg total EV protein in 20 μL PBS | Enhanced proliferation and migration of Schwann cells via the activation of JNK pathway and the up-regulation of c-Jun, Notch1, GFAP and SOX2 [54] |
| Cerebral artery stroke (in vitro) | Rat BMMSCs  | Sucrose gradient ultracentrifugation (100,000×g) | Details not provided | Neurite outgrowth by transfer of miR-133b to neural cells [55] |
| Cerebral artery stroke         | Rat BMMSCs  | Sucrose gradient ultracentrifugation (100,000×g) | Injection/100 μg total EV protein in 500 μL PBS | Improved recovery of brain function by increasing the number of number of neurons and endothelial cells in the lesion boundary zone and dentate gyrus [59] |
| TBI                            | Rat BMMSCs  | ExoQuick-TC kit (System Biosciences) | Injection/100 μg total EV protein in 500 μL PBS | Increased axonal density and synaptophysin-positive areas along the ischemic boundary zone of the cortex and striatum [58] |
| SCI                            | Mouse BMMSCs | Differential centrifugation and sequential ultracentrifugation (up to 110,000×g) | Injection/200 μL derived from 1 × 10⁶ MSCs post-SCI and 200 μL derived from 1 × 10⁶ MSCs at 1-day post-injury | Reduced migration of pericytes and improved structural integrity of the BSCB [62] |
| SCI                            | Rat BMMSCs  | Differential centrifugation and ultracentrifugation (100,000×g) | Injection/200 μg total EV protein in 200 μL PBS | Reduced neuronal apoptosis through the activation of the Wnt/β-catenin signalling pathway [63] |
| SCI                            | Rat BMMSCs  | ExoQuick-TC kit (System Biosciences) | Injection/100 μg total EV protein in 500 μL PBS | Modification of rat BMMSC-EVs with miR-133b activated the ERK1/2, STAT3 pathway, which resulted to enhanced neuron preservation [64] |
| MS                             | Human placental MSCs | Differential centrifugation and ultracentrifugation (112,700×g) | Injection/1 × 10⁷ or 1 × 10¹⁰ particles in 200 μL PBS | Increased myelination in the spinal cord of treated mice and improved motor function [65] |
### Table 1. Cont.

| Injury/Damage   | Cell Source          | Isolation Method                                      | Administration Route/Quantity | Main Findings from Studies Evaluating These EVs |
|-----------------|----------------------|-------------------------------------------------------|------------------------------|-----------------------------------------------|
| EAE             | Human BMMSCs         | Differential centrifugation and ultracentrifugation   | Injection/500 µg of total EV protein | Reduced neuroinflammation, demyelination and improved motor function |
| Alzheimer's disease | Details not included | Differential centrifugation and ultracentrifugation   | Injection/10 µg total EV protein in 2 µL PBS | Enhanced neurogenesis and cognitive function recovery [67] |
| Critical-sized calvarial defect | Human BMMSCs         | Differential centrifugation and ultracentrifugation   | Injection/100 µg total EV protein in 30 µL PBS | Increased cardiac repair, left ventricular function, vascularization, and reduced apoptosis and hypertrophy [74] |
| MI              | Human embryonic MSCs | Sucrose gradient centrifugation (200,000 x g)         | Injection/3 µg total EV protein in 200 µL PBS | Aki-modified MSC-EVs promoted endogenous angiogenesis, tube-like structure formation, and blood vessel formation [73] |
| MI              | Human embryonic MSCs | Tangential flow filtration                            | Infusion/0.4 µg total EV protein in 1 mL PBS | Increased myocardial viability and inhibited adverse remodelling [72] |
| MI              | Human UCMSCs         | Sucrose gradient centrifugation (100,000 x g)         | Injection/4.5 µg total EV protein | Improved cardiac regeneration via paracrine modulation of endogenous mechanisms [75] |
| MI              | Murine iPSCs         | Differential centrifugation and ultracentrifugation   | Injection/100 µg total EV protein in 100 µL PBS | BMSCs and their derived EVs synergistically improved cardiac function, reduced infarct size, and increased neovascularization [76] |
| MI              | Human BMSCs          | Ultracentrifugation (100,000 x g)                     | Injection/80 µg total EV protein | Hypoxia-elicited BMSC-EVs showed higher cardiac regeneration as compared to MSC-EVs isolated in normoxia [79] |
| MI              | Murine BMSCs         | Differential centrifugation and ultracentrifugation   | Injection/200 µg total EV protein in 200 µL PBS | Hypoxia-elicited BMSC-EVs prevented cardiomyocyte apoptosis through the enrichment of miR-125b-5p [80] |
| MI              | Rat BMSCs            | Repeated ultracentrifugation                          | Injection/EVs derived from 2 x 10^7 MSCs, in 30 µL PBS | Hyoxia-elicited BMSC-EVs enhanced the cardioprotective actions of EVs [81] |
| MI              | Human UCMSCs         | Total exosome isolation kit (Life Technologies)       | EV-hydrogel transplantation/20 µg of total EV protein in 20 µL PBS | Sustain delivery of MSC-EVs improved myocardial function by reducing inflammation, fibrosis and apoptosis, and by promoting angiogenesis [82] |
| Critical-sized calvarial defect | Human BMSCs         | Differential centrifugation and ultracentrifugation   | EV-hydrogel transplantation/100 µg of total EV protein in 50 µL PBS | Increased angiogenesis and bone formation [83] |
| Critical-sized calvarial defect | Human iPSCs          | Ultrafiltration and gradient ultracentrifugation (100,000 x g) | EV-scaffold transplantation/100 µg or 200 µg of total EV protein | Increased angiogenesis, osteogenesis and bone formation [84] |
| Critical-sized calvarial defect | Human BMSCs         | Differential centrifugation and ultracentrifugation   | Injection to implanted scaffolds/100 µg of total EV protein in 200 µL PBS | BMSC-EVs modified with dimethylfumarate enhanced bone regeneration through Akt/mTOR pathway activation and angiogenesis stimulation [85] |
| Bone regeneration (in vitro) | Human ADMSCs         | Ultracentrifugation (100,000 x g)                     | Details not provided | TNFα-primed ADMSC-EVs enhanced proliferation and differentiation of osteoblastic cells by increasing the expression of Wnt-3a [86] |
| Injury/Damage                      | Cell Source                      | Isolation Method                  | Administration Route/Quantity | Main Findings from Studies Evaluating These EVs                                                                 |
|-----------------------------------|----------------------------------|-----------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------|
| Femoral shaft fracture (CD9<sup>−</sup> and wild types) | Human BMMSCs | Ultracentrifugation (180,000 × g) | Injection / details not provided | Improved fracture healing in CD9<sup>−</sup>-mice, and accelerated bone repair in wild types [87]            |
| Tooth root slice                  | Human dental pulp MSCs           | ExoQuick-TC kit (System Biosciences) | Injection / details not provided | Increased odontogenic differentiation regeneration of dental pulp-like tissue [88]                             |
| Periodontal defect                | Unknown                          | Tangential flow filtration        | EV-scaffold transplantation/40 µg of total EV protein | Enhanced periodontal ligament cell migration, proliferation and periodontal regeneration [89]               |
| Critical-sized skull defect       | Human ADMSCs                    | Differential centrifugation and ultracentrifugation (100,000 × g) | EV-scaffold transplantation/l µg of total EV protein in 1 µL PBS | MSC-EVs immobilised in poly(lactic-co-glycolic acid) stimulated the controlled release of EVs promoting MSC migration and homing in the bone defects [90] |
| Ectopic bone formation            | Human ADMSCs                    | Differential centrifugation       | EV-scaffold transplantation/10 µg of total EV protein in 1 mL PBS | MSC-EV immobilised constructs showed higher osteo-inductive ability and long-term stability for bone graft modification [91] |
| Critical-sized calvarial defects  | Human BMMSCs                    | Differential centrifugation and sucrose gradient ultracentrifugation (100,000 × g) | EV-scaffold transplantation/5 × 10<sup>11</sup> or 1 × 10<sup>12</sup> particles in 1 mL PBS | BMSC-EVs loaded into tricalcium phosphate scaffolds promoted osteogenesis activity and bone regeneration [92] |
| Ectopic bone formation            | Rat BMMSCs                       | Differential centrifugation       | EV-scaffold transplantation/20 µg of total EV protein in 20 µL PBS | MSC-EVs loaded into decalcified bone matrix scaffolds stimulated neo-vascularization and bone formation [93] |
| Cortical calvaria bone defect     | Human gingival MSCs              | ExoQuick-TC kit (System Biosciences) | EV-scaffold transplantation/details not provided | MSC-EVs loaded in three-dimensional poly(lactic acid) scaffolds enhanced osteogenic properties and improved bone healing [94] |

**Cartilage**

| OA                                | Human amniotic fluid MSCs       | Total exosome isolation kit (Life Technologies) | Injection/100 µg of total EV protein | EV-treated defects showed superior pain tolerance level and improved histological scores than the MSC-treated defects [96] |
| Cartilage regeneration (in vitro) | Human BMMSCs                    | Differential centrifugation and ultracentrifugation (100,000 × g) | Details not provided | Increased production of collagen type II and proteoglycans in chondrocytes isolated from OA patients [97] |
| OA                                | Human BMMSCs                    | Differential centrifugation and sucrose gradient ultracentrifugation (100,000 × g) | Injection/500 µg of total EV protein in 1 mL PBS | BMSC-EVs modified with miR-92a-3p, suppressed cartilage degradation by targeting the WNT5A and promoted cartilage repair [100] |
| OA                                | Rat MSCs                        | Tangential flow filtration         | Injection/1 × 10<sup>11</sup> particles in 1 mL PBS | TGFβ1 primed MSC-EVs promoted cartilage tissue repair through Sp1 regulation [101] |
| OA                                | Human embryonic MSCs            | Tangential flow filtration         | Injection/100 µg of total EV protein in 100 µL PBS | Increased chondrocyte proliferation, reduced apoptosis, regulated inflammation and matrix homeostasis [102–104] |
| OA                                | Human embryonic MSCs            | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection / details not provided | Improved osteoarthritis through balancing the synthesis and degradation of cartilage ECM [105] |
| Cartilage defect                  | Human UCSCs                     | Differential centrifugation and ultracentrifugation (110,000 × g) | Injection/1 × 10<sup>10</sup> particles in 1 mL PBS | UCMSCs cultured in a bioreactor resulted in a higher yield of EVs and superior therapeutic efficiency [106] |
| Articular cartilage defect        | Human iPSCs                     | Differential centrifugation, ultracentrifugation (100,000 × g) and ultrafiltration | EV-scaffold transplantation/1 × 10<sup>11</sup> particles in 1 mL PBS | iPSC-EVs incorporated with in situ hydrogel glue could integrate with native cartilage matrix and promote cell deposition at cartilage defect [107] |
| Injury/Damage          | Cell Source       | Isolation Method                        | Administration Route/Quantity | Main Findings from Studies Evaluating These EVs                                                                 |
|-----------------------|-------------------|-----------------------------------------|------------------------------|----------------------------------------------------------------------------------------------------------------|
| Osteochondral defect  | BMMSCs            | Ultrafiltration and sucrose gradient ultracentrifugation (100,000×g) | EV-scaffold transplantation/200 µg of total EV protein in 200 µL PBS | BMMSC-EVs together with cartilage ECM/ gelatin methacrylate hydrogel have been used to create a 3D printed device, which favoured cartilage regeneration [109] |
| AKI                   | Human BMMSCs      | Ultracentrifugation (100,000×g)         | Injection/15 µg of total EV protein | Enhanced recovery of injured tubular cells, enhanced tubular cell proliferation, reduced apoptosis [110] |
| AKI (in vitro)        | Human BMMSCs      | Ultracentrifugation (100,000×g)         | Details not provided | Increased renoprotection activity mediated by the transfer of the mRNA for IGF-1 receptor to tubular cells through the MSC-EVs [113] |
| AKI                   | Human BMMSCs      | Ultracentrifugation (100,000×g)         | Injection/30 µg of total EV protein | Enhanced tubular epithelial cell proliferation, reduced cell apoptosis [114] |
| AKI                   | Mice BMMSCs       | Sequential ultracentrifugation (up to 110,000×g) | Injection/200 µg of total EV protein in 20 µL PBS | Enhanced tubular epithelial cell proliferation, reduced cell apoptosis [115] |
| AKI                   | Human BMMSCs      | Ultracentrifugation (100,000×g)         | Injection/Single dose of 100 µg of total EV protein or multiple doses of 108 µg of total EV protein after cisplatin administration and 50 µg of total EV protein after 2, 6, 10, 14, and 18 days | Upregulated expression of anti-apoptotic genes in cisplatin-treated human tubular epithelial cells and down-regulated expression of cell-apoptotic genes [116] |
| AKI                   | Mice BMMSCs       | Differential centrifugation and ultracentrifugation (100,000×g) | EV or EV-hydrogel injection/80 µg of total EV protein in 15 µL PBS or 80 µg of total EV protein in 15 µL of hydrogel solution | BMMSC-EVs loaded to self-assembling peptide nanofiber hydrogel, showed better EV efficacy and improved renal function [117] |
| AKI                   | Human UCMSCs      | Differential centrifugation and sucrose gradient centrifugation (100,000×g) | Injection/200 µg of total EV protein | Reduced oxidative stress and renal tubular cell apoptosis, increased renal cell proliferation [118] |
| AKI                   | Human UCMSCs      | Ultracentrifugation (100,000×g)         | Injection/30 µg of total EV protein | Increased tubular cell proliferation and dedifferentiation [119] |
| AKI                   | Human Wharton’s Jelly MSCs | Ultracentrifugation (100,000×g)         | Injection/100 µg of total EV protein in 1 mL medium 199 | Improved renal function by enhancing tubular cell proliferation and reduced inflammation and apoptosis via mitochondrial fission [120,121] |
| AKI                   | Human glomerular MSCs | Ultracentrifugation (100,000×g)         | Injection/EVs derived from 1 × 10^5 cells in 120 µL PBS (T-CD133^+ EVs: 480 × 10^3/mouse; MSC-EVs: 400 × 10^3/mouse; MSC-EV-float: 400 × 10^3/mouse; Fibroblasts-EVs: 230 × 10^3/mouse) | Enhanced renal recovery [122] |
| AKI                   | Human liver MSCs  | Ultracentrifugation (100,000×g)         | Injection/EVs derived from 3.5 × 10^6 or 10 × 10^5 MSCs | Enhanced renal function through increased tubular cell proliferation and inhibition of apoptosis [123] |
| CDK                   | Human urinary MSCs | Ultracentrifugation (100,000×g) followed by sucrose gradient ultracentrifugation (100,000×g) | Injection/100 µg of total EV protein in 200 µL PBS | Reduced CKD progression by inhibiting podocyte apoptosis and promoting vascular regeneration and cell survival [125] |

Table 1. Cont.
### Table 1. Cont.

| Injury/Damage | Cell Source | Isolation Method | Administration Route/Quantity | Main Findings from Studies Evaluating These EVs |
|---------------|-------------|------------------|-------------------------------|-----------------------------------------------|
| CDK           | Rat urinary MSCs | Total exosome isolation kit (Life Technologies) | Injection/5.3 x 10^9 particles in 200 µL PBS | Improved renal morphology through the anti-apoptotic behaviour of tubular epithelial cells [126] |
| CDK           | Human BMMSCs and human liver MSCs | Ultracentrifugation (100,000× g) | Injection/1 x 10^10 particles for each injection once a week for 4 weeks (5 injections) | Reduced CDK progression through miRNAs capable of down-regulating profibrotic genes [127] |
| CDK           | Human liver MSCs | Sucrose gradient ultracentrifugation (350,000× g) and ultracentrifugation (100,000× g) | Injection/1 x 10^10 particles in 1 mL PBS for each injection once a week for 4 weeks | Reduced CDK progression through miRNAs capable of down-regulating profibrotic genes [128] |
| CDK           | Mice BMMSC | Ultracentrifugation (100,000× g) | Injection/30 µg of total EV protein (3 doses) | Protected renal injury via microRNA-dependent repairing [129,130] |
| CDK           | Human BMMSCs | ExoQuick-TC ULTRA (EQUltra-20TC-1, SBI) | Injection/4 x 10^7 particles in 2 mL PBS | Improved renal function by repairing the damage to apical and basolateral membranes and mitochondria of kidney proximal tubules [131] |
| Grade III-IV CKD (clinical trial) | Human UCMSCs | Ultracentrifugation (100,000× g) | Injection/100 µg of total EV protein per kg per dose (2 doses) | Reduced the progression of CDK [132] |

### Liver

| Injury/Damage | Cell Source | Isolation Method | Administration Route/Quantity | Main Findings from Studies Evaluating These EVs |
|---------------|-------------|------------------|-------------------------------|-----------------------------------------------|
| Carbon tetrachloride (CCl4)-induced liver injury | Human embryonic MSCs | Tangential flow filtration and chromatography | Injection/0.4 µg of total EV protein in 100 µL PBS | Increased hepatocyte proliferation and reduced apoptosis [133] |
| Hepatic ischemia-reperfusion injury | Human iPSCs | Differential centrifugation and ultracentrifugation | Injection/600 µg of total EV protein in 400 µL PBS | Enhanced hepatic regeneration via inhibition of apoptosis of hepatic cells, suppression of inflammatory and attenuation of the oxidative stress response [134] |
| Hepatic ischemia-reperfusion injury | Human iPSCs | ExoQuick Exosome Precipitation Solution (SBI Systems Biosciences) | Injection/2.5 x 10^12 particles in 500 µL PBS | Increased hepatocyte proliferation in vitro and in vivo in a dose-dependent manner [135] |
| Hepatic ischemia-reperfusion injury | Human UCMSCs | Ultracentrifugation (100,000× g) | Injection/10 mg of total EV protein per kg | Reduced infiltration of neutrophils and oxidative stress in hepatic tissue [139] |
| Chronic hepatic fibrosis | Human embryonic MSCs | Differential centrifugation and ultracentrifugation (100,000× g) | EV-hydrogel injection/350 µg of total EV protein in 400 µL PEG hydrogel solution | Sustained release of MSC-EVs from PEG hydrogels protected against hepatic failure [140] |

### Muscle

| Injury/Damage | Cell Source | Isolation Method | Administration Route/Quantity | Main Findings from Studies Evaluating These EVs |
|---------------|-------------|------------------|-------------------------------|-----------------------------------------------|
| Cardiotoxin-induced muscle injury | Human BMMSCs | Sequential ultracentrifugation (110,000× g) | Injection/details not provided | Enhanced muscle regeneration through increased myogenesis and angiogenesis [141] |
| Cardiotoxin-induced muscle injury | Human amniotic fluid MSCs | Ultracentrifugation (200,000× g) | Injection/details not provided | Enhanced muscle regeneration through regulation of inflammation and angiogenesis [142] |
| Tibialis anterior muscle damage | Human ADMSCs | Ultracentrifugation (200,000× g) | Injection/EVs derived from 1 x 10^6 cells | Enhanced muscle regeneration through the synergistic effect of EVs and soluble proteins [143] |
| Muscle degeneration associated with tear rotator cuffs | Human ADMSCs | Differential centrifugation and ultracentrifugation (100,000× g) | Injection/1 x 10^11 particles in 20 µL PBS | Enhanced myofiber regeneration and biomechanical properties of muscles in rotator cuffs [144] |
| Pubococygeus muscle injury | Human urine-derived MSCs | Differential centrifugation and ultracentrifugation (100,000× g) | Injection/1 x 10^10 particles in 1 mL PBS | Enhanced muscle regeneration through the activation, proliferation, and differentiation of muscle satellite cells [145] |
Table 1. Cont.

| Injury/Damage                              | Cell Source         | Isolation Method                  | Administration Route/Quantity | Main Findings from Studies Evaluating These EVs                                                                 |
|--------------------------------------------|---------------------|-----------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------|
| Muscle damage associated to critical limb ischemia | Human ADMSCs        | Ultracentrifugation (100,000 × g) | Injection/1 × 10^{10} particles intravenously or intramuscularly after intervention, 0.5 × 10^{10} via intramuscular injection after day 1 and 2 | Enhanced muscle regeneration/protection through NRG1-mediated signals [146] |
| Fibroblasts from normal and chronic wound patients (in vitro) | Human BMMSCs        | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/160 µg total EV protein in 160 µL PBS at wound sites and 40 µg total EV protein in 40 µL PBS at wound beds | Increased collagen synthesis and angiogenesis [150] |
| Skin wound                                 | Human iPSC          | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/200 µg of total EV protein in 200 µL PBS | Enhanced wound healing by regulating the collagen distribution secreted by fibroblasts in the early and late stage of wound healing [152] |
| Photo-damaged dermal fibroblasts (in vitro) | Human ADMSCs        | Tangential flow filtration        | 1 × 10^{8} particles in 1 mL PBS | Increased collagen and elastin synthesis and decreased metalloproteinase activity [151] |
| Skin wound                                 | Human ADMSCs        | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/200 µg of total EV protein in 200 µL PBS | Enhanced proliferation and migration of fibroblasts and tube formation by endothelial cells [149] |
| Excisional skin wound                      | Human ADMSCs        | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/200 µg of total EV protein in 200 µL PBS | Enhanced proliferation and migration of fibroblasts and tube formation by endothelial cells [149] |
| Ischemic wound                             | Human ADMSCs        | ExoQuick-TC kit (System Biosciences) | Injection/100 µg total EV protein in 1 mL PBS | Enhanced wound healing through migration and proliferation of dermal fibroblasts [154] |
| Cutaneous wound                            | Rabbit ADMSCs and BMMSCs | Ultracentrifugation (100,000 × g) | Injection/EVs derived from 10 × 10^{5} MSCs | Significant better wound healing upon treatment with ADMSC-EVs [155] |
| Second-degree burn wound                   | Human UCMSCs        | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/200 µg of total EV protein in 200 µL PBS | Enhanced wound healing through increased fibroblasts proliferation and angiogenesis and reduced skin cell apoptosis [156–158] |
| Skin wound                                 | Human UCMSCs        | Differential centrifugation and ultracentrifugation (120,000 × g) | Injection/200 µg of total EV protein in 100 µL PBS | Enhanced wound healing and reduced scar formation through inhibition of myofibroblast differentiation [159] |
| Injuries in lung cells (in vitro)          | Human placenta MSC  | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/200 µg of total EV protein in 200 µL PBS | Enhanced wound healing and reduced scar formation through inhibition of myofibroblast differentiation [159] |
| Influenza virus-induced acute lung injury   | Swine BMMSCs        | Ultracentrifugation (25,000 rpm) | Intratracheally/EVs produced by 10 × 10^{5} MSCs | Reduced virus shedding, production of proinflammatory cytokines, and influenza virus-induced lung lesions [161] |
| Lung injury induced by haemorrhagic shock and trauma | Human BMMSCs      | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/100 µg of total EV protein in 1 mL PBS | Improved pulmonary vascular permeability through the activation of proteins and pathways linked to cytoskeletal rearrangement [162] |
| Hyperlipidaemia                            | Human placenta MSC  | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/100 µg of total EV protein in 1 mL PBS | Reduced calcification of synthetic vascular grafts by immunomodulation and improved vascular function [163] |
Table 1. Cont.

| Injury/Damage                      | Cell Source     | Isolation Method                                      | Administration Route/Quantity            | Main Findings from Studies Evaluating These EVs |
|-----------------------------------|-----------------|-------------------------------------------------------|-----------------------------------------|------------------------------------------------|
| Neointimal hyperplasia (in vitro) | Human ADMSCs    | Differential centrifugation and ultracentrifugation (100,000 × g) | 100 µg of total EV protein in 1 mL PBS | Reduced abnormal proliferation and migration of vascular smooth muscle cell [164] |
| Hind-limb ischemia                | Human UCMSCs    | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/2 × 10^10 particles in 1 mL PBS | Enhanced angiogenesis and muscle regeneration, and ischemic limb function [165] |
| Tracheoesophageal fistulas         | Porcine ADMSCs  | Ultracentrifugation (100,000 × g)                      | EV-gel injection/1.3 × 10^{11} particles in 1 mL of pluronic F127 gel | Enhanced oesophageal fistula healing through targeted delivery of EVs embedded in thermo-responsive hydrogels [166] |
| Ulcerative colitis                | Mouse BMMSCs    | Differential centrifugation and ultracentrifugation (100,000 × g) | Injection/50 µg of total EV protein per day for 7 days | Improved symptoms through stimulating M2 macrophage polarization and negative inflammatory response [167] |

Moreover, human UCMSC-EVs have been reported to intensively promote the healing of second-degree burn wounds in vivo, mediated mainly by the activation of Wnt/β-catenin signalling pathway and subsequent increased dermal fibroblasts proliferation, angiogenesis, and reduced skin cell apoptosis [156–158]. Wound healing and suppressed scar formation have been facilitated by inhibiting myofibroblast differentiation at the site of skin defects by treating with human UCMSC-EVs. This therapeutic benefit of EVs has been particularly credited to the activities of specific microRNAs (namely, miR-21, -23a, -125b, and -145) [159].

4.9. The Regenerative Effect of MSC-EVs on Various Tissues

Aside from their reported beneficial therapeutic effect on the mentioned tissues and organs, MSC-EVs have been examined for their ability to restore or, indeed, improve the performance of many other organs and body systems—such as lungs, blood vessels, oesophagus and bowel— in case of injuries or diseases. For instance, it was reported that human placenta MSC-EVs could attenuate injuries (upon lipopolysaccharide stimulation) caused in lung cells in vitro [160]. In vivo, swine BMMSC-EVs improved lung function in a pig model of influenza virus-induced acute lung injury [161]. Furthermore, human BMMSC-EVs have been shown to alleviate pulmonary vascular permeability and lung injury induced by haemorrhagic shock and trauma in a mouse model, through the activation of proteins and pathways linked to cytoskeletal rearrangement of vascular permeability [162]. Additionally, human placenta MSC-EVs have been shown to inhibit calcification of synthetic vascular grafts by immunomodulation and improving vascular performance and functionality and in a rat model of hyperlipidaemia [163]. Likewise, EVs isolated from ADMSCs limited the abnormal proliferation and migration of vascular smooth muscle cells, followed by neointimal hyperplasia in the setting of vein graft bypass surgery [164]. Administration of human UCMSC-EVs in a mouse model of hind-limb ischemia ameliorated severe ischemic injury, as revealed by increased limb perfusion and function [165]. With respect to tracheoesophageal diseases such as fistulas, ADMSC-EVs embedded in thermo-responsive hydrogels ensured the targeted delivery of EVs at the site of porcine oesophageal fistula; this, in turn, augmented healing. The proposed mechanism here involved the inhibition of myofibroblast proliferation and fibrosis, the decline of inflammatory response, and the enhancement of angiogenesis [166]. Finally, administration of mouse BMMSC-EVs improved the symptoms of ulcerative colitis in a dextran sodium sulfate-induced mouse model, by stimulating M2 macrophage polarisation and blocking inflammatory response [167].
5. Conclusions and Future Perspectives

As reviewed here, due to their intrinsic therapeutic capacity EVs derived from MSCs—of a range of origins—represent a powerful tool for the treatment of many injuries and diseases, opening multiple novel avenues for tissue engineering and regenerative medicine strategies. While the number of clinical studies is limited to date (Table 2), there is evidence to show that the beneficial effects of MSC-EVs could be further enhanced by bioengineering and genetic modification; stimulation with a variety of different biophysical and biochemical stimuli; drug encapsulation; and nanomaterial science.

Table 2. List of clinical trials using MSC-EVs against tissue injuries *.

| Tissue Injury/Disease | Condition | Treatment | Trial Phase | Trial ID       |
|-----------------------|-----------|-----------|-------------|---------------|
| Lung injury           | Healthy   | Aerosol inhalation of allogenic ADMSC-EVs (2 × 10^8 particles/ml or 1 × 10^8 particles/3 ml) | Phase I | NCT04313647 |
| Lung disease (pneumonia) | Coronavirus disease-19 | Aerosol inhalation of allogenic ADMSC-EVs (2 × 10^8 particles/3 ml) for 5 days | Phase I | NCT04276987 |
| Chronic lung disease | Bronchopulmonary dysplasia | Intravenous infusion of BMMSC-EVs (20 or 60 or 200 pmol phospholid/kg body weight) | Phase I | NCT03857841 |
| Cartilage injury      | Osteoarthritis | Osteochondral explants from arthroplasty patients treated with ADMSC-EVs | Phase I | NCT04223622 |
| Brain injury          | Acute ischemic stroke | Administration of allogenic MSC-EVs enriched with miR-124 (200 µg total EV protein) via Stereotaxis | Phase II | NCT03384433 |
| Skin injury           | Dystrophic Epidermolysis Bullosa | Allogenic BMMSC-EVs locally administered | Phase II | NCT04173650 |
| Kidney disease        | CDK       | Injection of allogenic UMMSC-EVs (100 µg of total EV protein per kg per dose) | Phase II/III (completed) | [132] |

* Information obtained from https://clinicaltrials.gov/ on 8 April 2020.

However, there are still challenges to the development of MSC-EVs for clinical use. From a practical point-of-view, a major challenge is establishing the optimal reliably, reproducible and robust methodologies for isolation and purification of the therapeutic EVs and their large-scale production at cGMP standard for clinical utility. Moreover, maybe yet from a more fundamental research point-of-view is to establish which sub-populations (if not all) of the heterogenous EV populations are therapeutically beneficially. The clear classification into different subtypes is still under investigation. Further research is also warranted to establish suitable therapeutic doses and optimal route(s) of administration for clinical utility in the future.

Author Contributions: Conceptualization, D.T. and L.O.; writing—original draft preparation, D.T.; writing—review and editing, L.O. and D.T.; funding acquisition, L.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the EU Commission as Horizon 2020 project EVPRO [H2020-NMBP-TR-IND-2018] and the Irish Research Council Advanced Laureate Award, EVIC [IRCLA/2019/49].

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Black, C.K.; Termanini, K.M.; Aguirre, O.; Hawksworth, J.S.; Sosin, M. Solid organ transplantation in the 21st century. *Ann. Transl. Med.* 2018, 6, 409. [CrossRef]
2. Platt, J.; Cascalho, M. New and old technologies for organ replacement. *Curr. Opin. Organ Transplant.* **2013**, *18*, 179–185. [CrossRef] [PubMed]

3. Langer, R.; Vacanti, J.P. Tissue engineering. *Science* **1993**, *260*, 920–926. [CrossRef]

4. Fitzsimmons, R.; Mazurek, M.S.; Soos, A.; Simmons, C.A. Mesenchymal stromal/stem cells in regenerative medicine and tissue engineering. *Stem Cells Int.* **2018**, *2018*, 1–16. [CrossRef] [PubMed]

5. Cossu, G.; Birchall, M.; Brown, T.; De Coppi, P.; Culme-Seymour, E.; Gibbon, S.; Hitchcock, J.; Mason, C.; Montgomery, J.; Morris, S.; et al. Lancet Commission: stem cells and regenerative medicine. *Lancet* **2018**, *391*, 883–910. [CrossRef]

6. Howard, D.; Buttery, L.; Shakesheff, K.M.; Roberts, S.J. Tissue engineering: strategies, stem cells and scaffolds. *J. Anat.* **2008**, *213*, 66–72. [CrossRef]

7. Le Blanc, K.; Ringdén, O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. *Blood Marrow Transplant.* **2005**, *11*, 321–334. [CrossRef]

8. Samsonraj, R.M.; Raghunath, M.; Nurcombe, V.; Hui, J.H.; Van Wijnen, A.J.; Cool, S.M. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. *STEM CELLS Transl. Med.* **2017**, *6*, 2173–2185. [CrossRef]

9. O’Brien, T.; Creane, M.; Windebank, A.J.; Terzic, A.; Dietz, A.B. Translating stem cell research to the clinic: a primer on translational considerations for your first stem cell protocol. *Stem Cell Res. Ther.* **2015**, *6*, 146. [CrossRef]

10. Amer, M.H.; Rose, F.R.A.J.; Shakesheff, K.M.; Modo, M.; White, L. Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges. *NPJ Regen. Med.* **2017**, *2*, 23. [CrossRef]

11. Volarevic, V.; Markovic, B.S.; Gazdic, M.; Volarevic, A.; Jovicic, N.; Arsenijevic, N.; Armstrong, L.; Djonov, V.; Lako, M.; Stojkovic, M. Ethical and safety issues of stem cell-based therapy. *Int. J. Med Sci.* **2018**, *15*, 36–45. [CrossRef]

12. MacPherson, A.; Kimmelman, J. Ethical development of stem-cell-based interventions. *Nat. Med.* **2019**, *25*, 1037–1044. [CrossRef] [PubMed]

13. Zakrzewski, W.; Dobrzyński, M.; Szymonowicz, M.; Rybak, Z. Stem cells: past, present, and future. *Stem Cell Res. Ther.* **2019**, *10*, 68. [CrossRef] [PubMed]

14. Gould, S.J.; Raposo, G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. *J. Extracell. Vesicles* **2013**, *2*, 2892. [CrossRef] [PubMed]

15. Yuana, Y.; Sturk, A.; Nieuwland, R. Extracellular vesicles in physiological and pathological conditions. *Blood Rev.* **2013**, *27*, 31–39. [CrossRef] [PubMed]

16. Ludwig, A.-K.; Giebel, B. Exosomes: Small vesicles participating in intercellular communication. *Int. J. Biochem. Cell Biol.* **2012**, *44*, 11–15. [CrossRef] [PubMed]

17. Yáñez-Mó, M.; Siljander, P.; Andreu, Z.; Zavec, A.B.; Borrás, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* **2015**, *4*, 27066. [CrossRef] [PubMed]

18. Van Der Pol, E.; Boing, A.N.; Harrison, P.; Sturk, A.; Nieuwland, R. Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol. Rev.* **2012**, *64*, 676–705. [CrossRef]

19. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, E.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018: a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J. Extracell. Vesicles* **2018**, *7*, 1535750. [CrossRef]

20. Han, C.; Sun, X.; Liu, L.; Jiang, H.; Shen, Y.; Xu, X.; Li, J.; Zhang, G.; Huang, J.; Lin, Z.; et al. Exosomes and their therapeutic potentials of stem cells. *Stem Cells Int.* **2015**, *2015*, 1–11. [CrossRef]

21. Tolar, J.; Le Blanc, K.; Keating, A.; Blazar, B.R. Concise review: hitting the right spot with mesenchymal stromal cells. *STEM CELLS* **2010**, *28*, 1446–1455. [CrossRef] [PubMed]

22. Lai, R.C.; Yeo, R.W.Y.; Lim, S.K. Mesenchymal stem cell exosomes. *Semin. Cell Dev. Biol.* **2015**, *40*, 82–88. [CrossRef]

23. Lener, T.; Gimona, M.; Aigner, L.; Börger, V.; Buzas, E.; Camussi, G.; Chaput, N.; Chatterjee, D.; Court, F.A.; Del Portillo, H.A.; et al. Applying extracellular vesicles based therapeutics in clinical trials—An ISEV position paper. *J. Extracell. Vesicles* **2015**, *4*, 30087. [CrossRef] [PubMed]
24. Tögel, F.; Weiss, K.; Yang, Y.; Hu, Z.; Zhang, P.; Westenfelder, C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. *Am. J. Physiol. Physiol. 2007*, 292, F1626–F1635. [CrossRef] [PubMed]

25. Yeo, R.W.Y.; Lai, R.C.; Zhang, B.; Tan, S.S.; Yin, Y.; Teh, B.J.; Lim, S.K. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. *Adv. Drug Deliv. Rev. 2013*, 65, 336–341. [CrossRef]

26. Park, K.-S.; Bandeira, E.; Shelke, G.V.; Lässer, C.; Lötvall, J. Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. *Stem Cell Res. Ther. 2019*, 10, 288. [CrossRef]

27. Catalano, M.; O’Driscoll, L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. *J. Extracell. Vesicles 2019*, 9, 1703244. [CrossRef]

28. Shifrin, D.A.; Beckler, M.D.; Coffey, R.J.; Tyska, M.J. Extracellular vesicles: communication, coercion, and conditioning. *Mol. Biol. Cell 2013*, 24, 1253–1259. [CrossRef]

29. Zhang, Y.; Liu, Y.; Liu, H.; Tang, W.H. Exosomes: biogenesis, biologic function and clinical potential. *Cell Biosci. 2019*, 9, 19. [CrossRef]

30. Caruso, S.; Poon, I.K.H. Apoptotic cell-derived extracellular vesicles: more than just debris. *Front. Immunol. 2018*, 9, 1486. [CrossRef]

31. Mobarrez, F.; Sjövik, C.; Soop, A.; Hållström, L.; Frostell, C.; Pisetsky, D.S.; Wallén, H. CD40L expression in plasma of volunteers following LPS administration: a comparison between assay of CD40L on platelet microvesicles and soluble CD40L. *Platelets 2014*, 26, 1–5. [CrossRef] [PubMed]

32. Jeppesen, D.; Fenix, A.M.; Franklin, J.I.; Higginbotham, J.N.; Zhang, Q.; Zimmerman, L.J.; Liebler, D.C.; Ping, J.; Liu, Q.; Evans, R.; et al. Reassessment of exosome composition. *Cell 2019*, 177, 428–445.e18. [CrossRef] [PubMed]

33. Crowley, L.; Marfell, B.J.; Scott, A.P.; Waterhouse, N.J. Quantitation of apoptosis and necrosis by annexin v binding, propidium iodide uptake, and flow cytometry. *Cold Spring Harb. Protoc. 2016*. [CrossRef]

34. Record, M.; Silvente-Poirot, S.; Poirot, M.; Wakelam, M. Extracellular vesicles: lipids as key components of their biogenesis and functions. *J. Lipid Res. 2018*, 59, 1316–1324. [CrossRef]

35. Daly, M.; O’Driscoll, L. MicroRNA Profiling of exosomes. *Adv. Struct. Saf. Stud. 2016*, 1509, 37–46.

36. Trionfini, P.; Benigni, A.; Remuzzi, G. MicroRNAs in kidney physiology and disease. *Nat. Rev. Nephrol. 2014*, 11, 23–33. [CrossRef]

37. Pfeifer, P.; Werner, N.; Jansen, F. Role and function of microRNAs in extracellular vesicles in cardiovascular biology. *BioMed Res. Int. 2015*, 2015, 1–11. [CrossRef]

38. Lee, Y.S.; Dutta, A. MicroRNAs in cancer. *Annu. Rev. Pathol. 2009*, 4, 199–227. [CrossRef]

39. Gardiner, C.; Di Vizio, L.; Sahoo, S.; Théry, C.; Wittwer, K.W.; Wauben, M.; Hill, A.F. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. *J. Extracell. Vesicles 2015*, 2, 72066. [CrossRef] [PubMed]

40. Ludwig, N.; Whiteside, T.L.; Reichert, T. Challenges in exosome isolation and analysis in health and disease. *Int. J. Mol. Sci. 2019*, 20, 4684. [CrossRef] [PubMed]

41. Zhang, M.; Jin, K.; Gao, L.; Zhang, Z.; Li, F.; Zhou, F.; Zhang, L. Methods and technologies for exosome isolation and characterization. *Small Methods 2018*, 2, 180021. [CrossRef]

42. Doyle, L.M.; Wang, M.Z. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. *Cells 2019*, 8, 727. [CrossRef] [PubMed]

43. Konoshenko, M.Y.; Lekchnov, E.A.; Vlassov, A.V.; Laktionov, P.P. Isolation of extracellular vesicles: general methodologies and latest trends. *BioMed Res. Int. 2018*, 2018, 8545347. [CrossRef] [PubMed]

44. García-Manrique, P.; Matos, M.; Gutierrez, G.; Pazos, C.; Blanco-López, M.C. Therapeutic biomaterials based on extracellular vesicles: classification of bio-engineering and mimetic preparation routes. *J. Extracell. Vesicles 2018*, 7, 1422676. [CrossRef]

45. Jeong, D.; Jo, W.; Yoon, J.; Kim, J.; Gianchandani, S.; Gho, Y.S.; Park, J. Nanovesicles engineered from ES cells for enhanced cell proliferation. *Biomaterials 2014*, 35, 9302–9310. [CrossRef]

46. Yoon, J.; Jo, W.; Jeong, D.; Kim, J.; Jeong, H.; Park, J. Generation of nanovesicles with sliced cellular membrane fragments for exogenous material delivery. *Biomaterials 2015*, 59, 12–20. [CrossRef]
48. Forterre, A.; Jalabert, A.; Berger, E.; Baudet, M.; Chikh, K.; Errazuriz, E.; De Larichaudy, J.; Chanon, S.; Weiss-Gayet, M.; Hesse, A.M.; et al. Proteomic analysis of C2C12 myoblast and myotube exosome-like vesicles: a new paradigm for myoblast-myotube cross talk? PLoS ONE 2014, 9, e84153.

49. Boni, R.; Ali, A.; Shavandi, A.; Clarkson, A. Current and novel polymeric biomaterials for neural tissue engineering. J. Biomed. Sci. 2018, 25, 90. [CrossRef]

50. Ma, Y.; Ge, S.; Zhang, J.; Zhou, D.; Li, L.; Wang, X.; Su, J. Mesenchymal stem cell-derived extracellular vesicles promote nerve regeneration after sciatic nerve crush injury in rats. Int. J. Clin. Exp. Pathol. 2017, 10, 10032–10039.

51. Ma, Y.; Dong, L.; Zhou, D.; Li, L.; Zhang, W.; Zhen, Y.; Wang, T.; Su, J.; Chen, D.; Mao, C.; et al. Extracellular vesicles from human umbilical cord mesenchymal stem cells improve nerve regeneration after sciatic nerve transaction in rats. J. Cell. Mol. Med. 2019, 23, 2822–2835. [CrossRef] [PubMed]

52. Bucan, V.; Vaslaitis, D.; Peck, C.-T.; Strauss, S.; Vogt, P.M.; Radtke, C. Effect of exosomes from rat adipose-derived mesenchymal stem cells on neurite outgrowth and sciatic nerve regeneration after crush injury. Mol. Neurobiol. 2018, 56, 1812–1824. [CrossRef] [PubMed]

53. Haertinger, M.; Weiss, T., Mann, A.; Tabi, A.; Brandel, V.; Radtke, C. Adipose stem cell-derived extracellular vesicles induce proliferation of Schwann cells via internalization. Cells 2020, 9, 163. [CrossRef]

54. Mao, Q.; Nguyen, P.D.; Shanti, R.M.; Shi, S.; Shakoori, P.; Zhang, Q.; Le, A.D. Gingiva-derived mesenchymal stem cell-extracellular vesicles activate Schwann cell repair phenotype and promote nerve regeneration. Tissue Eng. Part A 2019, 25, 887–900. [CrossRef]

55. Xin, H.; Li, Y.; Buller, B.; Katakowski, M.; Zhang, Y.; Wang, X.; Shang, X.; Zhang, Z.G.; Chopp, M. Exosome-mediated transfer of miR-133b from multidentipotent mesenchymal stem cells to neural cells contributes to neurite outgrowth. STEM CELLS 2012, 30, 1556–1564. [CrossRef]

56. Couillard-Despres, S.; Winner, B.; Schaubeck, S.; Aigner, R.; Brandel, V.; Radtke, C. Adipose stem cell-derived extracellular vesicles promote Schwann cell repair phenotype and promote nerve regeneration. J. Neurosurg. 2015, 122, 856–867. [CrossRef] [PubMed]

57. Zanetta, L.; Marcus, S.G.; Vasile, J.; Dobryansky, M.; Cohen, H.; Eng, K.; Shamamian, P.; Mignatti, P. Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int. J. Cancer 2000, 85, 281–288. [CrossRef]

58. Xin, H.; Li, Y.; Cui, Y.; Yang, J.J.; Zhang, Z.G.; Chopp, M. Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. Br. J. Pharmacol. 2013, 33, 1711–1715. [CrossRef]

59. Zhang, Y.; Chopp, M.; Meng, Y.; Katakowski, M.; Xin, H.; Mahmood, A.; Xiong, Y. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J. Neurosurg. 2015, 122, 856–867. [CrossRef]

60. Cheng, J.; Korte, N.; Nortley, R.; Sethi, H.; Tang, Y.; Attwell, D. Targeting pericytes for therapeutic approaches to neurological disorders. Acta Neuropathol. 2018, 136, 507–523. [CrossRef]

61. Figley, S.A.; Khashovski, R.; Legasto, J.M.; Tseng, Y.-F.; Fehlings, M.G. Characterization of vascular disruption after sciatic nerve crush injury in rats. Int. J. Clin. Exp. Pathol. 2017, 10, 10032–10039.

62. Lu, Y.; Zhou, Y.; Zhang, R.; Wen, L.; Wu, K.; Li, Y.; Yao, Y.; Duan, R.; Jia, Y. Bone mesenchymal stem cell-derived extracellular vesicles promote recovery following spinal cord injury via improvement of the integrity of the blood-splnal cord barrier. Front. Mol. Neurosci. 2019, 13, 209. [CrossRef] [PubMed]

63. Li, C.; Jiao, G.; Wu, W.; Wang, H.; Ren, S.; Zhang, L.; Zhou, H.; Liu, H.; Chen, Y. Exosomes from bone marrow mesenchymal stem cells inhibit neuronal apoptosis and promote motor function recovery via the Wnt/beta-catenin signaling pathway. Cell Transplant 2019, 28, 1373–1383. [CrossRef] [PubMed]

64. Li, N.; Zhang, P.; Yao, X.; Li, H.; Shen, H.; Li, X.; Wu, J.; Lu, X. Exosomes derived from mir-133b-modified mesenchymal stem cells promote recovery after spinal cord injury. Front. Mol. Neurosci. 2018, 12, 845. [CrossRef]

65. Clark, K.; Zhang, S.; Barthe, S.; Kumar, P.; Pivetti, C.D.; Kreutzberg, N.; Reed, C.; Wang, Y.; Paxton, Z.J.; Farmer, D.L.; et al. Placental mesenchymal stem cell-derived extracellular vesicles promote myelin regeneration in an animal model of multiple sclerosis. Cells 2019, 8, 1497. [CrossRef]
66. Riazifar, M.; Mohammadi, M.R.; Pone, E.J.; Yeri, A.; Lässer, C.; Segaliny, A.I.; McIntyre, L.L.; Shelke, G.; Hutchins, E.; Hamamoto, A.; et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. *ACS Nano* **2019**, *13*, 6670–6688. [CrossRef]

67. Canales-Aguirre, A.A.; Reza-Zaldivar, E.E.; Sapiens, M.A.H.; Gutiérrez-Mercado, Y.K.; Sandoval-Ávila, S.; Gomez-Pinedo, U.; Márquez-Aguirre, A.L.; Vazquez-Mendez, E.; Padilla-Camberos, E. Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer’s disease. *Neural Regen. Res.* **2019**, *14*, 1626–1634. [CrossRef]

68. Madeddu, P.; Urbanek, K.; Kajstura, J.; Yan, S.; Finato, N.; Hussain, R.; Nadal-Ginard, B.; Silvestri, F.; Leri, A.; Beltrami, C.A.; et al. Evidence that human cardiac myocytes divide after myocardial infarction. *New Engl. J. Med.* **2001**, *344*, 1750–1757.

69. Senyo, S.; Steinhauser, M.L.; Pizzimenti, C.L.; Yang, V.K.; Cai, L.; Wang, M.; Wu, T.-D.; Guerquin-Kern, J.-L.; Skupien-Rabian, B.; Chen, X.; et al. Induced pluripotent stem cell (iPSC)–derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs. *Stem Cells Transl. Med.* **2017**, *6*, 51–59.

70. Adamiak, M.; Cheng, G.; Bobis-Wozowicz, S.; Zhao, L.; Kedracka-Krok, S.; Samanta, A.; Karnas, E.; Xuan, Y.-T.; Skupien-Rabian, B.; Chen, X.; et al. Induced pluripotent stem cell (iPSC)–derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs. *Circ. Res.* **2018**, *122*, 296–309. [CrossRef]

71. Balbi, C.; Lodder, K.; Costa, A.; Moimas, S.; Moccia, F.; Van Herwaarden, T.; Rosti, V.; Campagnoli, F.; Palmeri, A.; De Biasio, P.; et al. Reactivating endogenous mechanisms of cardiac regeneration via paracrine boosting using the human amniotic fluid stem cell secretome. *Int. J. Cardiol.* **2019**, *287*, 87–95. [CrossRef]

72. Huang, P.; Wang, L.; Li, Q.; Xu, J.; Xu, J.; Xiong, Y.; Chen, G.; Qian, H.; Jin, C.; Yu, Y.; et al. Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance. *Stem Cell Res. Ther.* **2019**, *10*, 300–312. [CrossRef]

73. Hu, X.; Xu, Y.; Zhong, Z.; Wu, Y.; Zhao, J.; Wang, Y.; Cheng, H.; Kong, M.; Zhang, F.; Chen, Q.; et al. A large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman primate senescence and significance. *Circ. Res.* **2016**, *118*, 970–983. [CrossRef]

74. Biao, S.; Zhang, L.; Duan, L.; Wang, X.; Min, Y.; Yu, H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. *J. Mol. Med.* **2013**, *91*, 387–397. [CrossRef]

75. Zhu, J.; Lu, K.; Zhang, N.; Zhao, Y.; Ma, Q.; Shen, J.; Lin, Y.; Xiang, P.; Tang, Y.; Hu, X.; et al. Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way. *Artif. Cells Nanomed. Biotechnol.* **2018**, *46*, 1659–1670. [PubMed]
82. Han, C.; Zhou, J.; Liang, C.; Liu, B.; Pan, X.; Zhang, Y.; Wang, Y.; Yan, B.; Xie, W.; Liu, F.; et al. Human umbilical cord mesenchymal stem cell derived exosomes encapsulated in functional peptide hydrogels promote cardiac repair. *Biomater. Sci.* 2019, 7, 2920–2933. [CrossRef]

83. Qin, Y.; Wang, L.; Gao, Z.; Chen, G.; Zhang, C. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. *Sci. Rep.* 2016, 6, 21961. [CrossRef]

84. Qi, X.; Zhang, J.; Yuan, H.; Xu, Z.; Li, Q.; Niu, X.; Hu, B.; Wang, Y.; Li, X.-L. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats. *Int. J. Biol. Sci.* 2016, 12, 836–849. [CrossRef]

85. Liang, B.; Liang, J.-M.; Ding, J.-N.; Xu, J.; Xu, J.-G.; Chai, Y. Dimethylxaloylglycine-stimulated human bone marrow mesenchymal stem cell-derived exosomes enhance bone regeneration through angiogenesis by targeting the AKT/mTOR pathway. *Stem Cell Res. Ther.* 2019, 10, 1–11. [CrossRef] [PubMed]

86. Lu, Z.; Chen, Y.; Dunstan, C.; Roohani-Esfahani, S.-I.; Zreiqat, H. Priming adipose stem cells with tumor necrosis factor-alpha preconditioning potentiates their exosome efficacy for bone regeneration. *Tissue Eng. Part A* 2017, 23, 1212–1220. [CrossRef] [PubMed]

87. Furuta, T.; Miyaki, S.; Ishitobi, H.; Ogura, T.; Kato, Y.; Kamei, N.; Miyado, K.; Higashi, Y.; Ochi, M. Mesenchymal stem cell-derived exosomes promote fracture healing in a mouse model. *STEM CELLS Transl. Med.* 2016, 5, 1620–1630. [CrossRef]

88. Huang, C.-C.; Narayanan, R.; Alapati, S.; Ravindran, S. Exosomes as biomimetic tools for stem cell differentiation: Applications in dental pulp tissue regeneration. *Biomaterial 2016, 111, 103–115. [CrossRef] [PubMed]

89. Chew, J.R.J.; Chuah, S.J.; Teo, K.Y.W.; Zhang, S.; Lai, R.C.; Fu, J.H.; Lim, L.P.; Lim, S.K.; Toh, W.S. Mesenchymal stem cell exosomes enhance periodontal ligament cell functions and promote periodontal regeneration. *Acta Biomater.* 2019, 89, 252–264. [CrossRef]

90. Li, W.; Liu, Y.; Zhang, P.; Tang, Y.; Zhou, M.; Jiang, W.; Zhang, X.; Wu, G.; Zhou, Y. Tissue-engineered bone immobilized with human adipose stem cells-derived exosomes promotes bone regeneration. *ACS Appl. Mater. Interfaces* 2018, 10, 5240–5254. [CrossRef]

91. Chen, L.; Mou, S.; Li, F.; Zeng, Y.; Sun, Y.; Horch, R.E.; Wei, W.; Wang, Z.; Sun, J. Self-assembled human adipose-derived stem cell-derived extracellular vesicle-functionalized biotin-doped polypryrolyl titanium with long-term stability and potential osteoinductive ability. *ACS Appl. Mater. Interfaces* 2019, 11, 46183–46196. [CrossRef] [PubMed]

92. Zhang, J.; Liu, X.; Li, H.; Chen, C.-Y.; Hu, B.; Niu, X.; Li, Q.; Zhao, B.; Xie, Z.; Wang, Y. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway. *Stem Cell Res. Ther.* 2016, 7, 136. [CrossRef] [PubMed]

93. Xie, H.; Wang, Z.; Zhang, L.; Lei, Q.; Zhao, A.; Wang, H.; Li, Q.; Cao, Y.; Zhang, W.J.; Chen, Z.-C. Extracellular vesicle-functionalized decalcified bone matrix scaffolds with enhanced pro-angiogenic and pro-bone regeneration activities. *Sci. Rep.* 2017, 7, 45622. [CrossRef]

94. Diomedes, F.; Gugliandolo, A.; Cardelli, P.; Merciario, I.; Ettorre, V.; Traini, T.; Bedini, R.; Scionti, D.; Bramanti, A.; Nanci, A.; et al. Three-dimensional printed PLA scaffold and human gingival stem cell-derived extracellular vesicles: a new tool for bone defect repair. *Stem Cell Res. Ther.* 2018, 9, 104. [CrossRef]

95. Loeser, R.F.; Goldring, S.R.; Scanzello, C.R.; Goldring, M.B. Osteoarthritis: A disease of the joint as an organ. *Arthritis Rheum.* 2012, 64, 1697–1707. [CrossRef]

96. Zavatti, M.; Beretti, F.; Casciaro, F.; Bertucci, E.; Maraldi, T. Comparison of the therapeutic effect of amniotic fluid stem cells and their exosomes on monoiodoacetate-induced animal model of osteoarthritis. *BioFactors* 2019, 46, 106–117. [CrossRef]

97. Vonk, L.A.; Van Dooremalen, S.F.J.; Liv, N.; Klumperman, J.; Coffer, P.J.; Saris, D.B.; Lorenowicz, M.J. Mesenchymal stromal/stem cell-derived extracellular vesicles promote human cartilage regeneration in vitro. *Theranostics* 2018, 8, 906–920. [CrossRef]

98. Gao, Y.; Liu, S.; Huang, J.; Guo, W.; Chen, J.; Zhang, L.; Zhao, B.; Peng, J.; Wang, A.; Wang, Y.; et al. The ECM-cell interaction of cartilage extracellular matrix on chondrocytes. *BioMed Res. Int.* 2014, 2014, 1–8. [CrossRef]

99. Hosseini-Farahabadi, S.; Geetha-Loganathan, P.; Fu, K.; Nimmagadda, S.; Yang, H.J.; Richman, J.M. Dual functions for WNT5A during cartilage development and in disease. *Matrix Biol.* 2013, 32, 252–264. [CrossRef]
100. Mao, G.; Zhang, Z.; Hu, S.; Zhang, Z.; Chang, Z.; Huang, Z.; Liao, W.; Kang, Y. Exosomes derived from miR-92a-3p-overexpressing human mesenchymal stem cells enhance chondrogenesis and suppress cartilage degradation via targeting WNT5A. Stem Cell Res. Ther. 2018, 9, 247. [CrossRef]

101. Wang, R.; Xu, B.; Xu, H. TGF-beta1 promoted chondrocyte proliferation by regulating Sp1 through MSC-exosomes derived miR-135b. Cell Cycle 2018, 17. [CrossRef]

102. Zhang, S.; Chuah, S.J.; Lai, R.C.; Hui, J.H.P.; Lim, S.K.; Toh, W.S. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterial 2018, 156, 16–27. [CrossRef]

103. Zhang, S.; Chu, W.C.; Lai, R.C.; Lim, S.K.; Hui, J.H.P.; Toh, W.S. Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration. Osteoarthr. Cartil. 2016, 24, 2135–2140. [CrossRef]

104. Zhang, S.; Teo, K.Y.W.; Chuah, S.J.; Lai, R.C.; Lim, S.K.; Toh, W.S. MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis. Biomaterial 2019, 200, 35–47. [CrossRef]

105. Wang, Y.; Yu, D.; Liu, Z.; Zhou, F.; Dai, J.; Wu, B.; Zhou, J.; Heng, B.C.; Zou, X.H.; Ouyang, H.; et al. Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. Stem Cell Res. Ther. 2017, 8, 189. [CrossRef]

106. Yan, L.; Wu, X. Exosomes produced from 3D cultures of umbilical cord mesenchymal stem cells in a hollow-fiber bioreactor show improved osteochondral regeneration activity. Cell. Biol. Toxicol. 2019, 1–14. [CrossRef]

107. Liu, X.; Yang, Y.; Li, Y.; Niu, X.; Zhao, B.; Wang, Y.; Bao, C.; Xie, Z.; Lin, Q.; Zhu, L. Integration of stem cell-derived exosomes with in situ hydrogel glue as a promising tissue patch for articular cartilage regeneration. Nanoscale 2017, 9, 4430–4438. [CrossRef]

108. Bishop, E.; Mostafa, S.; Pakvasa, M.; Luu, H.H.; Lee, M.J.; Wolf, J.M.; Ameer, G.A.; He, T.-C.; Reid, R.R. 3-D bioprinting technologies in tissue engineering and regenerative medicine: Current and future trends. Genes Dis. 2017, 4, 185–195. [CrossRef]

109. Chen, P.; Zheng, L.; Wang, Y.; Tao, M.; Xie, Z.; Xia, C.; Gu, C.; Chen, J.; Qiu, P.; Mei, S.; et al. Desktop-stereolithography 3D printing of a radially oriented extracellular matrix/mesenchymal stem cell exosome bioink for osteochondral defect regeneration. Nanoscale 2017, 9, 4430–4438. [CrossRef]

110. Tomasoni, S.; Longaretti, L.; Rota, C.; Morigi, M.; Conti, S.; Gotti, E.; Capelli, C.; Introna, M.; Remuzzi, G.; Benigni, A. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2012, 22, 772–780. [CrossRef]

111. Gatti, S.; Bruno, S.; Deregibus, M.C.; Sordi, A.; Cantaluppi, V.; Tetta, C.; Camussi, G. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 2011, 26, 1474–1483. [CrossRef]

112. Shen, B.; Liu, J.; Zhang, F.; Wang, Y.; Qin, Y.; Zhou, Z.; Qu, J.; Fan, Y. CCR2 Positive Exosome released by mesenchymal stem cells suppresses macrophage functions and alleviates ischemia/reperfusion-induced renal injury. Stem Cells Int. 2016, 2016, 1–9. [CrossRef]

113. Bruno, S.; Grange, C.; Collino, F.; Deregibus, M.C.; Cantaluppi, V.; Biancone, L.; Tetta, C.; Camussi, G. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS ONE 2012, 7, e33115. [CrossRef]

114. Zhou, Y.; Liu, S.; Zhao, M.; Wang, C.; Li, L.; Yuan, Y.; Li, L.; Liao, G.; Bresette, W.; Zhang, J.; et al. Injectable extracellular vesicle-released self-assembling peptide nanofiber hydrogel as an enhanced cell-free therapy for tissue regeneration. J. Control. Release 2019, 316, 93–104. [CrossRef]
118. Zhou, Y.; Xu, H.; Xu, W.; Wang, B.; Wu, H.; Tao, Y.; Zhang, B.; Wang, M.; Mao, F.; Yan, Y.; et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res. Ther. 2013, 4, 34. [CrossRef]
119. Ju, G.-Q.; Cheng, J.; Zhong, L.; Wu, S.; Zou, X.-Y.; Zhang, G.-Y.; Gu, D.; Miao, S.; Zhu, Y.-J.; Sun, J.; et al. Microvesicles derived from human umbilical cord mesenchymal stem cells facilitate tubular epithelial cell dedifferentiation and growth via hepatocyte growth factor induction. PLoS ONE 2015, 10, e0121534. [CrossRef]
120. Gu, D.; Zou, X.; Ju, G.; Zhang, G.; Bao, E.; Zhu, Y. Mesenchymal stromal cells derived extracellular vesicles ameliorate acute renal ischemia-reperfusion injury by inhibition of mitochondrial fission through miR-30. Stem Cells Int. 2016, 2016, 1–12. [CrossRef]
121. Zou, X.; Zhang, G.; Cheng, Z.; Yin, D.; Du, T.; Ju, G.; Miao, S.; Liu, G.-H.; Lu, M.; Zhu, Y. Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. Stem Cell Res. Ther. 2014, 5, 40. [CrossRef]
122. Ranghino, A.; Bruno, S.; Bussolati, B.; Moggio, A.; DiMuccio, V.; Tapparo, M.; Biancone, L.; Gonterio, P.; Frea, B.; Camussi, G. The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury. Stem Cell Res. Ther. 2017, 8, 24. [CrossRef]
123. Sanchez, M.B.H.; Bruno, S.; Grange, C.; Tapparo, M.; Cantaluppi, V.; Tetta, C.; Camussi, G. Human liver stem cells and derived extracellular vesicles improve recovery in a murine model of acute kidney injury. Stem Cell Res. Ther. 2014, 5, 124. [CrossRef]
124. Piccoli, G.B.; Grassi, G.; Cabiddu, G.; Nazha, M.; Roggero, S.; Capizzi, I.; De Pascale, A.; Priola, A.M.; Di Vico, C.; Mazza, S.; et al. Diabetic kidney disease: a syndrome rather than a single disease. Rev. Diabet. Stud. 2015, 12, 87–109. [CrossRef]
125. Jiang, Z.-Z.; Liu, Y.-M.; Niu, X.; Yin, J.-Y.; Hu, B.; Guo, S.-C.; Fan, Y.; Wang, Y.; Wang, N. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Res. Ther. 2016, 7, 24. [CrossRef]
126. Nagaishi, K.; Mizue, Y.; Chikenji, T.; Otani, M.; Nakano, M.; Konari, N.; Fujiyama, M. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci. Rep. 2016, 6, 34842. [CrossRef]
127. Grange, C.; Tritta, S.; Tapparo, M.; Cedrino, M.; Tetta, C.; Camussi, G.; Brizzi, M.F. Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci. Rep. 2019, 9, 4486. [CrossRef]
128. Kholia, S.; Sanchez, M.B.H.; Cedrino, M.; Papadimitriou, E.; Tapparo, M.; Deregibus, M.C.; Brizzi, M.F.; Tetta, C.; Camussi, G. Human liver stem cell-derived extracellular vesicles prevent aristolochic acid-induced kidney fibrosis. Front. Immunol. 2018, 9, 9. [CrossRef]
129. He, J.; Wang, Y.; Sun, S.; Yu, M.; Wang, C.; Pei, X.; Zhu, B.; Wu, J.; Zhao, W. Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. Nephrology 2012, 17, 493–500. [CrossRef]
130. He, J.; Wang, Y.; Lu, X.; Zhu, B.; Pei, X.; Wu, J.; Zhao, W. Micro-vesicles derived from bone marrow stem cells protect the kidney both in vivo and in vitro by microRNA-dependent repairing. Nephrology 2015, 20, 591–600. [CrossRef]
131. Matsukura, T.; Inaba, C.; Weygant, E.A.; Kitamura, D.; Janknecht, R.; Matsumoto, H.; Hyink, D.P.; Kashiwada, S.; Obara, T. Extracellular vesicles from human bone marrow mesenchymal stem cells repair organ damage caused by cadmium poisoning in a medaka model. Physiol. Rep. 2019, 7, e14172. [CrossRef] [PubMed]
132. Nassar, W.; El-Ansary, M.; Sabry, D.; Fayad, T.; Kotb, E.; Temraz, M.; Saad, A.-N.; Essa, W.; Adel, H.; A Mostafa, M. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater. Res. 2016, 20, 21. [CrossRef] [PubMed]
133. Tan, C.Y.; Lai, R.C.; Wong, W.; Dan, Y.Y.; Lim, S.K.; Ho, H.K. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res. Ther. 2014, 5, 76. [CrossRef] [PubMed]
134. Nong, K.; Wang, W.; Niu, X.; Hu, B.; Ma, C.; Bai, Y.; Wu, B.; Wang, Y.; Ai, K. Hepatoprotective effect of exosomes from human-induced pluripotent stem cell–derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats. Cytotherapy 2016, 18, 1548–1559. [CrossRef]
135. Du, Y.; Li, D.; Han, C.; Wu, H.; Xu, L.; Zhang, M.; Zhang, J.; Chen, X. Exosomes from human-induced pluripotent stem cell–derived mesenchymal stromal cells (hiPSC-MSCs) protect liver against hepatic ischemia/reperfusion injury via activating sphingosine kinase and sphingosine-1-phosphate signaling pathway. *Cell. Physiol. Biochem.* 2017, 43, 611–625. [CrossRef]

136. Cannavo, A.; Liccardo, D.; Komici, K.; Corbi, G.; De Lucia, C.; Femminella, G.D.; Elia, A.; Bencivenga, L.; Ferrara, N.; Koch, W.J.; et al. Sphingosine kinases and sphingosine 1-phosphate receptors: signaling and actions in the cardiovascular system. *Front. Pharmacol.* 2017, 8. [CrossRef]

137. Blaho, V.A.; Hla, T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. *Chem. Rev.* 2011, 111, 6299–6320. [CrossRef]

138. Ng, M.L.; Yarla, N.S.; Menschikowski, M.; Sukocheva, O. Regulatory role of sphingosine kinase and sphingosine-1-phosphate receptor signaling in progenitor/stem cells. *World J. Stem Cells* 2018, 10, 119–133. [CrossRef]

139. Yao, J.; Zheng, J.; Cai, J.; Zeng, K.; Zhou, C.; Zhang, J.; Li, S.; Li, H.; Chen, L.; He, L.; et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate rat hepatic ischemia-reperfusion injury by suppressing oxidative stress and neutrophil inflammatory response. *FASEB J.* 2018, 33, 1695–1710. [CrossRef]

140. Mardpour, S.; Ghanian, M.H.; Abandansari, H.S.; Mardpour, S.; Nazari, A.; Shekari, F.; Baharvand, H. Hydrogel-mediated sustained systemic delivery of mesenchymal stem cell–derived extracellular vesicles improves hepatic regeneration in chronic liver failure. *ACS Appl. Mater. Interfaces* 2019, 11, 37421–37433. [CrossRef]

141. Nakamura, Y.; Miyaki, S.; Ishitobi, H.; Matsuyama, S.; Nakasa, T.; Kamei, N.; Akimoto, T.; Higashi, Y.; Ochi, M. Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration. *FEBS Lett.* 2015, 589, 1257–1265. [CrossRef] [PubMed]

142. Mellows, B.; Mitchell, R.; Antonioli, M.; Kretz, O.; Chambers, D.; Zeuner, M.-T.; Denecke, B.; Musante, L.; Ramachandra, D.L.; Deback-Chainaux, F.; et al. Protein and molecular characterization of a clinically compliant amniotic fluid stem cell-derived extracellular vesicle fraction capable of accelerating muscle regeneration through enhancement of angiogenesis. *Stem Cells Dev.* 2017, 26, 1316–1333. [CrossRef] [PubMed]

143. Mitchell, R.; Mellows, B.; Sheard, J.; Antonioli, M.; Kretz, O.; Chambers, D.; Zeuner, M.-T.; Tomkins, J.E.; Denecke, B.; Musante, L.; et al. Secretome of adipose-derived mesenchymal stem cells promotes skeletal muscle regeneration through synergistic action of extracellular vesicle cargo and soluble proteins. *Stem Cell Res. Ther.* 2019, 10, 116. [CrossRef]

144. Wang, C.; Song, W.; Chen, B.; Liu, X.; He, Y. Exosomes isolated from adipose-derived stem cells: a new cell-free approach to prevent the muscle degeneration associated with torn rotator cuffs. *Am. J. Sports Med.* 2019, 47, 3247–3255. [CrossRef]

145. Wu, R.; Huang, C.; Wu, Q.; Jia, X.; Liu, M.; Xue, Z.; Qiu, Y.; Niu, X.; Wang, Y. Exosomes secreted by urine-derived stem cells improve stress urinary incontinence by promoting repair of puboccygeus muscle injury in rats. *Stem Cell Res. Ther.* 2019, 10, 80. [CrossRef]

146. Figliolini, F.; Ranghino, A.; Grange, C.; Cedrino, M.; Tapparo, M.; Cavallari, C.; Rossi, A.; Togliatto, G.; Femminò, S.; Gugliuzza, M.V.; et al. Extracellular vesicles from adipose stem cells prevent muscle damage and inflammation in a mouse model of hind limb ischemia: role of Neuregulin-1. *Arter. Thromb. Vasc. Biol.* 2019, 40, 239–254. [CrossRef]

147. Veñnar, T.; Bailey, T.; Smrkolj, V. The wound healing process: an overview of the cellular and molecular mechanisms. *J. Int. Med Res.* 2009, 37, 1528–1542. [CrossRef]

148. Zhao, R.; Liang, H.; Clarke, E.; Jackson, C.; Xue, M. Inflammation in Chronic Wounds. *Int. J. Mol. Sci.* 2016, 17, 2085. [CrossRef]

149. Shabbir, A.; Cox, A.; Rodriguez-Menocal, L.; Salgado, M.; Van Badiavas, E. Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro. *Stem Cells Dev.* 2015, 24, 1635–1647. [CrossRef]

150. Zhang, J.; Guan, J.; Niu, X.; Hu, G.-W.; Guo, S.-C.; Li, Q.; Xie, Z.; Zhang, C.; Wang, Y. Exosomes released from human induced pluripotent stem cells–derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. *J. Transl. Med.* 2015, 13, 49. [CrossRef]
151. Choi, J.S.; Cho, W.L.; Choi, Y.J.; Kim, J.D.; Park, H.-A.; Kim, S.Y.; Park, J.H.; Jo, D.-G.; Cho, Y.W. Functional recovery in photo-damaged human dermal fibroblasts by human adipose-derived stem cell extracellular vesicles. *J. Extracell. Vesicles* 2019, 8, 1565885. [CrossRef] [PubMed]

152. Hu, L.; Wang, J.; Zhou, X.; Xiong, Z.; Zhao, J.; Yu, R.; Huang, F.; Zhang, H.; Chen, L. Exosomes derived from human adipose mesenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts. *Sci. Rep.* 2016, 6, 32993. [CrossRef] [PubMed]

153. Ferreira, A.D.F.; Cunha, P.D.S.; Carregal, V.; Silva, P.D.C.D.; De Miranda, M.C.; Kunrath-Lima, M.; De Melo, M.I.A.; Faraco, C.C.F.; Barbosa, J.L.; Frészard, F.; et al. Extracellular vesicles from adipose-derived mesenchymal stem/stromal cells accelerate migration and activate akt pathway in human keratinocytes and fibroblasts independently of miR-205 activity. *Stem Cells Int.* 2017, 2017, 9841035. [CrossRef] [PubMed]

154. Cooper, D.; Wang, C.; Patel, R.; Trujillo, A.; Patel, N.A.; Prather, J.; Gould, L.J.; Wu, M.H. Human adipose-derived stem cell conditioned media and exosomes containing MALAT1 promote human dermal fibroblast migration and ischemic wound healing. *Adv. Wound Care* 2018, 7, 299–308. [CrossRef]

155. Pelizzo, G.; Avanzini, M.; Cornaglia, A.I.; Silvestri, A.; Mantelli, M.; Travaglini, P.; Croce, S.; Romano, P.; Avolio, L.; Iacob, G.; et al. Extracellular vesicles derived from mesenchymal cells: perspective treatment for cutaneous wound healing in pediatrics. *Regen. Med.* 2018, 13, 385–394. [CrossRef]

156. Zhang, B.; Wang, M.; Gong, A.; Zhang, X.; Wu, X.; Zhu, Y.; Shi, H.; Wu, L.; Zhu, W.; Qian, H.; et al. HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. *STEM CELLS* 2015, 33, 2158–2168. [CrossRef]

157. Fang, S.; Xu, C.; Zhang, Y.; Xue, C.; Yang, C.; Bi, H.; Qian, X.; Wu, M.; Ji, K.; Zhao, Y.; et al. Umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt/beta-catenin pathway. *Stem Cells Transl. Med.* 2015, 4, 513–522. [CrossRef]

158. Kim, S.Y.; Joglekar, M.V.; Hardikar, A.A.; Phan, T.H.; Khanal, D.; Tharkar, P.; Limantoro, C.; Johnson, J.; Kalionis, B.; Chrzanowski, W. Placenta stem/stromal cell-derived extracellular vesicles for potential use in lung repair. *Proteom.* 2019, 19, e1800166. [CrossRef]

159. Wei, Y.; Wu, Y.; Zhao, R.; Zhang, K.; Midgley, A.C.; Kong, D.; Li, Z.; Zhao, Q. MSC-derived sEVs enhance patency and inhibit calcification of synthetic vascular grafts by immunomodulation in a rat model of hyperlipidemia. *Biomaterial* 2019, 204, 13–24. [CrossRef] [PubMed]

160. Almeria, C.; Weiss, R.; Roy, M.; Tripisciano, C.; Kasper, C.; Weber, V.; Egger, D. Hypoxia conditioned mesenchymal stem cell-derived extracellular vesicles induce increased vascular tube formation in vitro. *Front. Bioeng. Biotechnol.* 2019, 7, 292. [CrossRef] [PubMed]
166. Silva, A.K.A.; Perretta, S.; Perrod, G.; Pidial, L.; Lindner, V.; Carn, F.; Lemieux, S.; Alloyeau, D.; Boucenna, I.; Menasché, P.; et al. Thermoresponsive gel embedded with adipose stem-cell-derived extracellular vesicles promotes esophageal fistula healing in a thermo-actuated delivery strategy. *ACS Nano* **2018**, *12*, 9800–9814. [CrossRef]

167. Cao, L.; Xu, H.; Wang, G.; Liu, M.; Tian, D.; Yuan, Z. Extracellular vesicles derived from bone marrow mesenchymal stem cells attenuate dextran sodium sulfate-induced ulcerative colitis by promoting M2 macrophage polarization. *Int. Immunopharmacol.* **2019**, *72*, 264–274. [CrossRef]